Skip to content
⌘KStart free
AI InfrastructureDefenseQuantumAll studies →

AZN GB Equity

Astrazeneca PLC
London Stock Exchange+ CompareTear sheet →
Health Care · Pharmaceutical Preparations · CIK 901832 · FY ends Dec 31
$164.95
+4.85 (+3.03%)
USD · as of 2026-08-19 · marketstack

Clinical trials

catalyst calendar across sponsors →
3,473 registered studies · 499 active

Studies where AZN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

Of the 500 shown: 358 interventional · 142 observational · 56 with posted results

Held by 20 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, Holocene Advisors, LP, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, MARSHALL WACE, LLP, +15 more) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionReadout inUpdated
LTFU for All Cell and Gene Therapy StudiesNCT06194461observationalIncidence of specific AEs—Not yet recruitingBiological: AZD5851, AZD0754Hepatocellular Carcinoma, Prostate Cancer642041-11-29in 5,580 d2025-06-27
The Eplontersen Pregnancy and Lactation Outcomes StudyNCT07205666observationalMajor congenital malformations—Recruiting—Transthyretin Amyloidosis102035-12-30in 3,419 d2026-06-22
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian CancerNCT04830709observationalprogression-free survival (PFS)—Active, not recruiting—Ovarian Cancer7522033-03-31in 2,415 d2026-07-10
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803Metastasis-free survival (MFS)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)Prostate Cancer7002033-03-31in 2,415 d2026-07-21
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentNCT07691970SAEs and Non-Serious AEsNon-randomized · Open-label · TreatmentPhase 3Not yet recruitingCombination product: Anifrolumab, Anifrolumab · Drug: AnifrolumabSystemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus1,0722032-12-31in 2,325 d2026-07-09
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ AllianceNCT06726720observationalCohort A (resectable NSCLC)-Adjuvant rw DFS—Recruiting—Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance3002032-06-30in 2,141 d2026-06-01
Saphnelo Use in Females of Child-bearing PotentialNCT07431775observationalIncidence of anifrolumab use—Not yet recruitingDrug: AnifrolumabSystemic Lupus Erythematosus26,000,0002032-03-31in 2,050 d2026-02-25
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired SubpopulationsNCT07654855observationalDemographic and clinical characteristics of eplontersen users, including the prevalence of prior liver transplant and severe hepatic impairment—Not yet recruitingOther: None ( observational study )Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy, Transthyretin Amyloidosis With Polyneuropathy3202032-01-29in 1,988 d2026-06-17
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanNCT05573893observationalReal-world Time To Next Treatment (rwTTNT1)—Recruiting—Breast Neoplasms, Breast Cancer, Neoplasm Metastasis8002031-12-31in 1,959 d2026-08-12
Non-interventional Study of Patients With Transthyretin (ATTR) AmyloidosisNCT06465810observationalDemographic characteristics (overall and in patients initiating a treatment with eplontersen)—RecruitingDrug: Treatment of transthyretin (ATTR) amyloidosis in observational study settingTransthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR1,8502031-12-29in 1,957 d2026-08-19
Anifrolumab Malignancy and Serious Infections StudyNCT07000110observationalMalignancies—RecruitingDrug: AnifrolumabSystemic Lupus Erythematosus3,5062031-11-30in 1,928 d2026-08-13
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsNCT06549595SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEsRandomized · Open-label · TreatmentPhase 3RecruitingDrug: Surovatamig, R-CHOP, R-CVP, BRUntreated Follicular Lymphoma1,0182031-11-26in 1,924 d2026-08-19
Real-World Treatment Study of Koselugo (Selumetinib)NCT06360406observationalAdverse events (AEs) rate—Recruiting—Neurofibromatosis 1, Neurofibroma, Plexiform2002031-09-30in 1,867 d2026-07-22
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)NCT07509151DOSRI- Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs)Randomized · Open-label · TreatmentPhase 3RecruitingDrug: SurovatamigChronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV4202031-08-29in 1,835 d2026-08-10
A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.NCT07743944observationalPercentage of patients receiving different regimens in each Line of treatment (LoT)—Recruiting—Breast Cancer2,0002031-08-04in 1,810 d2026-08-04
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in ChinaNCT07593248observationalTo assess the effectiveness in real world of EGFR-TKI adjuvant therapy in resected NSCLC as measured by 5-year OS rate—Recruiting—Lung Cancer2,0002031-06-30in 1,775 d2026-08-13
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)NCT07711002Radiographic progression-free survival (rPFS)Randomized · Quadruple-masked · TreatmentPhase 3Not yet recruitingDrug: Saruparib, Enzalutamide, Darolutamide, Abiraterone · Other: PlaceboMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)1,3302031-06-17in 1,762 d2026-07-17
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersNCT06659029observationalComposite outcome of all major congenital malformations (MCMs)—RecruitingDrug: AnifrolumabSystemic Lupus Erythematosus4422031-04-15in 1,699 d2026-06-24
The Anifrolumab PRIM ProgramNCT06795893observationalMajor congenital malfunctions—RecruitingDrug: AnifrolumabSystemic Lupus Erythematosus2402031-04-15in 1,699 d2026-08-11
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerNCT05367440Number of patients with Adverse Events and Serious Adverse EventsNon-randomized · Open-label · TreatmentPhase 1/2Active, not recruitingDrug: AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, ApalutamideMetastatic Prostate Cancer1742031-04-11in 1,695 d2026-06-01
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesNCT03549754observational1. Age of particpants—Recruiting—Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure35,0002030-12-31in 1,594 d2026-07-22
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical PracticeNCT05637112observationalDisease activity assessed by the Physician Global Assessment (PGA)—Active, not recruitingOther: None (Observational study)Systemic Lupus Erythematosus5512030-12-30in 1,593 d2026-05-26
Observational Study Protocol: LIVER-RNCT06252753observationalReal-world overall survival (rwOS) in all participants—RecruitingOther: Durvalumab-based combination therapies in observational study setting, Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settingsHepatobiliary Cancers4,0002030-12-30in 1,593 d2026-08-13
Anifrolumab Pregnancy StudyNCT07049653observationalRisk of major congenital malformations (MCM)—Recruiting—Systemic Lupus Erythematosus5002030-12-10in 1,573 d2026-08-19
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647Overall survival (OS)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, PemetrexedNon-squamous Non-small Cell Lung Cancer1,1602030-11-18in 1,551 d2026-08-14
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.NCT07753993To evaluate the effect of elecoglipron compared with placebo in reducing the risk of the composite of ≥ 50% sustained decline in eGFR, ESKD, or all-cause mortalityRandomized · Quadruple-masked · TreatmentPhase 3Not yet recruitingDrug: Elecoglipron, PlaceboChronic Kidney Disease7,0002030-10-04in 1,506 d2026-08-10
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCNCT07720284To demonstrate the superiority of Dato-DXd + rilvegostomig (Arm 1) relative to SoC (Arm 3) by assessment of disease-free survival (DFS) (based on Investigator assessments).Randomized · Single-masked · TreatmentPhase 3RecruitingDrug: Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotinHigh-risk Muscle Invasive Urothelial Carcinoma9152030-09-11in 1,483 d2026-07-22
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus ErythematosusNCT07630714Maximum observed serum (peak) concentration (Cmax)Non-randomized · Open-label · TreatmentPhase 2Not yet recruitingCombination product: Anifrolumab + APFSSystemic Lupus Erythematosus242030-09-03in 1,475 d2026-06-05
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureNCT06651970Safety endpoints 1: To evaluate the incidence of CV (CardioVascular) adverse events leading to drug discontinuation after acalabrutinib treatment compared to investigators choice of treatment.Randomized · Open-label · OtherPhase 4RecruitingDrug: Acalabrutinib · Other: Investigator's choice of treatmentChronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment602030-08-16in 1,457 d2026-08-14
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738Overall survival (OS)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxelNon-small Cell Lung Cancer1,1602030-07-01in 1,411 d2026-08-13
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)NCT07624305Time from randomization to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure eventRandomized · Quadruple-masked · TreatmentPhase 3Not yet recruitingDrug: Balcinrenone/dapagliflozin, DapagliflozinRenal Insufficiency, Chronic2,8002030-07-01in 1,411 d2026-06-03
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCLNCT07215585SRI - Safety evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.Randomized · Open-label · TreatmentPhase 3RecruitingDrug: AZD0486, R-mini-CHOPLarge B-cell Lymphoma4202030-06-10in 1,390 d2026-06-18
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerNCT05061550Number of participants with pathological complete response (pCR)Randomized · Open-label · TreatmentPhase 2RecruitingDrug: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, RilvegostomigNon-small Cell Lung Cancer6302030-05-28in 1,377 d2026-07-23
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.NCT07279935To assess the efficacy of osimertinib + chemotherapy by evaluation of PFS in patients who had distant recurrence after adjuvant osimertinib.Open-label · TreatmentPhase 4RecruitingDrug: Osimertinib+cisplatin or carboplatin + pemetrexed EditNon-small Cell Lung Cancer1002030-05-18in 1,367 d2026-06-01
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaNCT05692180Time to first asthma exacerbationRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Benralizumab, PlaceboAsthma942030-05-05in 1,354 d2026-07-17
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLCNCT07760519observationalFrequency and proportion of patients with Grade 3/4 possibly related adverse events (PRAEs)*—Not yet recruitingOther: IMFINZICarcinoma, Non-Small-Cell Lung782030-04-30in 1,349 d2026-08-12
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent ChemoradiotherapyNCT06129864Progression-Free Survival (PFS) in participants with unresected LA-HNSCC with PD-L1 expressing tumorsRandomized · Single-masked · TreatmentPhase 3RecruitingDrug: volrustomigLocally Advanced Head and Neck Squamous Cell Carcinoma1,1452030-04-17in 1,336 d2026-08-06
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical RecordsNCT06842056observationalEarly stage (stage I and II with [N0])—Not yet recruiting—Lung Cancer3,0002030-03-31in 1,319 d2026-06-02
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursNCT07446855Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD4956, SaruparibSolid Tumours1802030-03-29in 1,317 d2026-08-11
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557Invasive breast cancer-free survival (IBCFS)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, AbemaciclibBreast Cancer, Early Breast Cancer5,5112030-03-04in 1,292 d2026-08-10
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With HyperkalaemiaNCT03813407Correction phase (CP) primary objective: To evaluate the ability to achieve normokalaemia during the CP when initiating treatment with SZC of different dose levels in children with hyperkalaemiaOpen-label · TreatmentPhase 3RecruitingDrug: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1), Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2), Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3), Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance PhaseHyperkalaemia1402030-02-21in 1,281 d2026-08-13
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277Overall Survival (OS)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingBiological: Rilvegostomig, PembrolizumabCarcinoma, Non-Small Cell Lung8302030-01-17in 1,246 d2026-08-03
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentNCT07444567Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumabNon-randomized · Open-label · TreatmentPhase 3RecruitingDrug: BenralizumabAsthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)2302030-01-03in 1,232 d2026-08-19
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia GravisNCT06909253observationalChange from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score—RecruitingDrug: RavulizumabMyasthenia Gravis, Generalized502029-12-31in 1,229 d2026-08-14
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in RussiaNCT07247279observationalAge at baseline (years)—Recruiting—Rare Diseases, Generalized Myasthenia Gravis (gMG)4502029-12-31in 1,229 d2026-08-12
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in BelarusNCT07288515observationalTime to treatment discontinuation—Recruiting—Chronic Lymphocytic Leukemia502029-12-31in 1,229 d2026-07-16
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)NCT07633158observationalMean change from baseline in sino-nasal symptoms measured by SNOT-22 total score at clinical routine visits.—Recruiting—Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)2002029-12-31in 1,229 d2026-07-29
The DEBATE Study "DEvelopment of Endotype-based Biomarkers for the Monitoring of Greek pATiEnts With CRSwNP"NCT07663409observationalCharacterization of nasal tissue-secreted cytokines/chemokines in patients with CRSwNP—RecruitingOther: Not applicable - NIS studyCRSwNP or CRSsNP Patients2302029-12-31in 1,229 d2026-07-22
CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREANCT06927648observationalAdverse Events (AEs)·Adverse Drug Reactions (ADRs) Serious Adverse Events (SAEs)·Adverse Drug Reactions (SADRs) Unexpected Adverse Events (AEs)·Adverse Drug Reactions (ADRs)—Recruiting—Breast Cancer1302029-12-30in 1,228 d2026-07-07
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNCT06357533Progression-Free Survival (PFS) in TROP2 biomarker positive participants.Randomized · Single-masked · TreatmentPhase 3RecruitingDrug: Datopotamab Deruxtecan, Rilvegostomig, PembrolizumabNon-Small Cell Lung Cancer6752029-12-28in 1,226 d2026-08-12
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751Progression-Free Survival (Arm 1 vs arm 2)Randomized · Open-label · TreatmentPhase 3RecruitingDrug: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, ExemestaneAdvanced Breast Cancer7882029-12-18in 1,216 d2026-07-30
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.NCT06542250Frequency of dose limiting toxicities (DLTs).Open-label · TreatmentPhase 1/2RecruitingDrug: AZD5492B-cell Malignancies1742029-12-18in 1,216 d2026-08-07
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death.Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Baxdrostat/dapagliflozin, Placebo/dapagliflozinChronic Kidney Disease and Hypertension5,0002029-12-18in 1,216 d2026-07-28
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060To determine if baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of an HF event or CV deathRandomized · Quadruple-masked · PreventionPhase 3RecruitingDrug: Baxdrostat and dapagliflozin · Other: Placebo and dapagliflozinHeart Failure11,3002029-12-17in 1,215 d2026-07-31
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)NCT05526755Estimate the Efficacy of Osimertinib as Measured by Disease Free Survival (DFS) [Common EGFRm Cohort].Open-label · TreatmentPhase 2Active, not recruitingDrug: Osimertinib 80 mg/40 mgStage II-IIIB Non-small Cell Lung Carcinoma1882029-11-22in 1,190 d2026-08-03
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)NCT05729711observationalIncidence of ADRs—Active, not recruiting—Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)4162029-11-16in 1,184 d2026-06-26
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in KoreaNCT06998095observationalIncidence proportion of AEs, ADRs, SAEs, SADRs, unexpected AEs/ADRs and unexpected SAEs/SADRs—Not yet recruiting—Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)2102029-10-31in 1,168 d2026-06-04
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaNCT07681596Adverse events (AEs) and serious AEs (SAEs)Non-randomized · Open-label · TreatmentPhase 1/2Not yet recruitingBiological: AZD4045 · Drug: Daratumumab, AldesleukinRelapsed or Refractory Multiple Myeloma1012029-10-30in 1,167 d2026-07-02
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First EventNCT07000357Time to first event of any component of MACE-PLUSRandomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: AZD0780, PlaceboCardiovascular Disease15,1002029-10-26in 1,163 d2026-07-02
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)Non-randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD6750, rilvegostomigMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma1202029-10-02in 1,139 d2026-08-19
Ravulizumab Outcomes in Polish Patients With aHUSNCT07399730observationalProportion of patient attaining Complete Thrombotic Microangiopathy (TMA) Response during observation (naïve)—RecruitingDrug: RavulizumabAtypical Hemolytic Uremic Syndrome802029-09-30in 1,137 d2026-08-18
PROLONG (PRostateOLaparibONcombinationGcc) StudyNCT07674121observationalEvaluate the time to treatment discontinuation (TTD) or death (event-free rate) at 6 and 12 months in 1L NHA pre-exposed mCRPC patients treated with Olaparib + Abiraterone.—Not yet recruitingDrug: Olaparib and Abiraterone CombinationMetastatic Castration-resistant Prostate Cancer (mCRPC)752029-09-30in 1,137 d2026-06-29
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerNCT07590934Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs)Randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD2265 (FPI-2265), AZD9574, Docetaxel, AZD2287 (Imaging agent)Metastatic Prostate Cancer1522029-09-25in 1,132 d2026-06-30
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117To evaluate the effect of elecoglipron compared with placebo in reducing the risk of CV death or HHF/urgent HF visitRandomized · Quadruple-masked · TreatmentPhase 3Not yet recruitingDrug: Elecoglipron, PlaceboHeart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)6,9502029-09-03in 1,110 d2026-08-12
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine CareNCT07424261observationalProportion and number of patients who fulfill criteria for definition of remission in SLE (DORIS remission)—Recruiting—Lupus Erythematosus, Systemic1252029-08-31in 1,107 d2026-06-24
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2NCT07431281Progression Free Survival (PFS) (Cohort 1 and Cohort 2)Randomized · Single-masked · TreatmentPhase 3RecruitingDrug: Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, LeucovorinGastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer2,1302029-08-16in 1,092 d2026-07-01
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumoursNon-randomized · Open-label · TreatmentPhase 1RecruitingBiological: NT-175Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)452029-07-31in 1,076 d2026-08-06
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)NCT07221253Overall Survival (OS) in the PDL1 ≥ 1% populationRandomized · Open-label · TreatmentPhase 3RecruitingDrug: Rilvegostomig, Durvalumab, Gemcitabine/CisplatinBiliary Tract Cancer1,1002029-07-31in 1,076 d2026-07-20
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmNCT055468663-year disease-free survival (DFS) rate by investigator assessmentOpen-label · TreatmentPhase 2Active, not recruitingDrug: OsimertinibNon-small Cell Lung Cancer512029-06-30in 1,045 d2026-08-06
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.NCT06992609To describe the safety profile of durvalumab for patients with LS-SCLC who have not progressed following CRT.Open-label · TreatmentPhase 3Active, not recruitingDrug: DurvalumabSmall Cell Lung Carcinoma682029-06-30in 1,045 d2026-07-27
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing SurveillanceNCT06995833observationalSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs/ADRs)—Recruiting—Endometrial Cancer502029-06-29in 1,044 d2026-06-24
Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese AdultsNCT07646600observationalchanges in cardiac imaging parameters, left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS)—Not yet recruitingOther: Observational, None interventionDilated Cardiomyopathy102029-06-29in 1,044 d2026-06-15
OSIREAL - Osimertinib RWE on EGFRm NSCLC in SpainNCT06068049observationalTo evaluate the effectiveness of osimertinib in terms of median OS in patients with locally advanced or metastatic EGFRm NSCLC (Cohort 1).—Recruiting—Non-small Cell Lung Cancer5002029-06-15in 1,030 d2026-07-22
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesNCT06564038Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special InterestNon-randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, AcalabrutinibChronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma4082029-06-11in 1,026 d2026-08-12
Tezspire Cardiac Events PASSNCT06951867observationalcomposite outcome MACE—RecruitingDrug: TezepelumabCardiovascular Events, MACE16,6402029-05-31in 1,015 d2026-07-27
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyNCT07295821PFS (Progression-Free Survival)Open-label · TreatmentPhase 2RecruitingDrug: OsimertinibLung Cancer602029-05-30in 1,014 d2026-04-08
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With AsthmaNCT07525375Change from baseline in Forced Expiratory volume in one second (FEV1) at 1-hour post-dose measured at End of treatment (EoT)Randomized · Triple-masked · TreatmentPhase 2RecruitingCombination product: GP MDI, BFF MDI, Placebo MDIAsthma692029-05-23in 1,007 d2026-04-22
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.NCT06137144Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD3470, PembrolizumabLymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL1612029-05-03in 987 d2026-06-24
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLENCT06897930PHASE 1B: To evaluate the safety and tolerability of AZD0120 in participants with refractory systemic lupus erythematosus (SLE)Open-label · TreatmentPhase 1/2RecruitingBiological: AZD0120 · Drug: Cyclophosphamide, FludarabineLupus Erythematosus, Systemic1502029-05-01in 985 d2026-08-12
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± ObinutuzumabNCT07024706Overall Response Rate (ORR)Non-randomized · Open-label · TreatmentPhase 2RecruitingDrug: Acalabrutinib, VenetoclaxChronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)802029-05-01in 985 d2026-08-06
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in ChinaNCT07316062observationalTreatment Patterns—Recruiting—Non-Small-Cell Lung3,0002029-04-30in 984 d2026-08-12
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerNCT06764875Progression free survival (PFS)Randomized · Single-masked · TreatmentPhase 3RecruitingDrug: Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil, Capecitabine, Cisplatin, OxaliplatinHER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma8402029-04-27in 981 d2026-06-16
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLNCT05952024Percentage of patients with Grade 3 to 4 treatment emergent adverse events (TEAEs)Open-label · TreatmentPhase 2RecruitingDrug: Acalabrutinib · Biological: RituximabDiffuse Large B-Cell Lymphoma802029-04-22in 976 d2026-08-06
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06879041Number of participants with adverse event (AEs)Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: AZD2287, AZD2275, AZD2284Metastatic Castration-Resistant Prostate Cancer1362029-04-16in 970 d2026-05-12
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)NCT07688980Anifrolumab serum concentrations through Week 4Randomized · Open-label · TreatmentPhase 1Not yet recruitingCombination product: Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFSSystemic Lupus Erythematosus922029-04-13in 967 d2026-07-07
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)NCT07098338Number of participants with adverse events (AE) and serious adverse events (SAE)Non-randomized · Open-label · TreatmentPhase 2RecruitingDrug: Rilvegostomig, Ramucirumab, Dato-DXdNon-Small Cell Lung Cancer2782029-04-06in 960 d2026-07-01
PICAROS - Acalabrutinib RWE on 1L CLL in SpainNCT05999877observationalProportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).—Active, not recruiting—Chronic Lymphocytic Leukemia1922029-03-31in 954 d2026-08-04
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)NCT06890273observationalReal-world Time To Next Treatment (rwTTNT)—Recruiting—Endometrial Cancer1502029-03-31in 954 d2026-06-24
BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine TherapyNCT07597993observationalreal-world progression-free survival—RecruitingDrug: TDxdBreast Cancer1092029-03-31in 954 d2026-08-10
SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBCNCT07701070observationalPrevalence of ESR1 mutations in circulating tumour DNA—Not yet recruitingOther: Blood samplingAdvanced Breast Cancer3,0002029-03-30in 953 d2026-07-14
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate CancerNCT07192614Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)Randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD6621Prostate Cancer522029-03-29in 952 d2026-07-29
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaNCT06921785To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCCRandomized · Single-masked · TreatmentPhase 3RecruitingDrug: Tremelimumab, Rilvegostomig, Bevacizumab, AtezolizumabHepatocellular Carcinoma1,2202029-03-16in 939 d2026-07-14
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)NCT06878261Annualised rate of moderate or severe COPD exacerbationsRandomized · Quadruple-masked · TreatmentPhase 3RecruitingBiological: Tezepelumab · Other: PlaceboChronic Obstructive Pulmonary Disease (COPD)9902029-03-13in 936 d2026-06-24
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305Annualised rate of moderate or severe COPD exacerbationsRandomized · Quadruple-masked · TreatmentPhase 3RecruitingBiological: Tezepelumab · Other: PlaceboChronic Obstructive Pulmonary Disease (COPD)9902029-03-13in 936 d2026-06-24
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.NCT05984277Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, PemetrexedMetastatic Non-small Cell Lung Cancer8952029-02-28in 923 d2026-07-28
Imjudo & Imfinzi PMSNCT06544629observationalSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs/ADRs)—Recruiting—Hepatocellular Carcinoma2462029-02-28in 923 d2025-11-21
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328Efficacy of camizestrant and ribociclib by time to next treatment (TTNT)Non-randomized · Open-label · TreatmentPhase 3RecruitingDrug: Camizestrant, RibociclibER-Positive HER2-Negative Breast Cancer1502029-02-28in 923 d2026-08-10
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)NCT06996782Part A and Part B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, RamucirumabAdvanced or Metastatic Non-small Cell Lung Cancer1522029-02-23in 918 d2026-07-21
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX OverexpressionNCT07155226Module 1: Number of participants with dose-limiting toxicity (DLT)Non-randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD3632, PosaconazoleAcute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes842029-02-15in 910 d2026-07-20
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110Radiographic Progression-Free Survival (rPFS)Randomized · Single-masked · TreatmentPhase 3RecruitingDrug: AZD2265, Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Rezvilutamide, Radium-223Metastatic Castration-resistant Prostate Cancer6702029-02-13in 908 d2026-07-01
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CMNCT07608354Cardiopulmonary exercise test peak VO2Randomized · Quadruple-masked · TreatmentPhase 2Active, not recruitingDrug: Eplontersen · Biological: ALXN2220 · Other: PlaceboTransthyretin Amyloid Cardiomyopathy (ATTR-CM)3262029-02-06in 901 d2026-07-14
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsNCT07291037Progression-free survival (PFS)Randomized · Open-label · TreatmentPhase 3RecruitingDrug: Datopotamab deruxtecan (Dato-DXd), DocetaxelNon-small Cell Lung Cancer (NSCLC)4002029-01-29in 893 d2026-07-01
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsNCT07336446Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)Randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD9750, AZD5305Prostate Cancer3002029-01-26in 890 d2026-08-10
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusNCT07430306Attainment of DORIS remissionNon-randomized · Open-label · TreatmentPhase 3RecruitingDrug: AnifrolumabSystemic Lupus Erythematosus2452029-01-26in 890 d2026-07-23
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerNCT06989112Progression-free survival (PFS), as assessed by BICRRandomized · Open-label · TreatmentPhase 3RecruitingDrug: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, DocetaxelEndometrial Cancer6002029-01-19in 883 d2026-08-11
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerNCT07181161Module 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs)Randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD0516, AZD9574Metastatic Prostate Cancer1772029-01-18in 882 d2026-07-15
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTNCT07764978PFS in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd.Randomized · Open-label · TreatmentPhase 3RecruitingBiological: AZD0120, Daratumumab, Isatuximab · Drug: Dexamethasone, Lenalidomide, Bortezomib, Cyclophosphamide, FludarabineNewly Diagnosed Multiple Myeloma7502029-01-11in 875 d2026-08-14
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)NCT06109779Recurrence free survival (RFS) for Arm A vs. Arm BRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]Biliary Tract Cancer7602029-01-02in 866 d2026-07-10
Fasenra Pediatric Japan Post-Marketing Study(PMS)NCT06427876observationalIncidence of ADRs—Active, not recruiting—Bronchial Asthma402028-12-31in 864 d2026-07-27
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in ItalyNCT07214753observationalNumber and percentage of patients achieving clinical remission, partial and complete, as per SANI Definition—RecruitingBiological: benralizumabSevere Eosinophilic Asthma3352028-12-31in 864 d2026-07-08
A Prospecitve Multicenter, Observational Registry StudyNCT07481526observationalProportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively—Recruiting—Chronic Kidney Disease3,0002028-12-30in 863 d2026-08-13
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of ExacerbationsNCT07566195Adverse eventsOpen-label · TreatmentPhase 3RecruitingDrug: Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2Chronic Obstructive Pulmonary Disease, COPD592028-12-29in 862 d2026-07-21
An Open-label Study of AZD0120 in Adults With Multiple SclerosisNCT07224373Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Randomized · Open-label · TreatmentPhase 1RecruitingBiological: AZD0120 - Regimen 1, AZD0120 - Regimen 2Multiple Sclerosis242028-12-12in 845 d2026-07-27
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid TumorsNCT06130553All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agentsOpen-label · TreatmentPhase 1/2RecruitingDrug: AZD3470, Datopotamab deruxtecanAdvanced Solid Tumors That Are MTAP Deficient3342028-12-04in 837 d2026-07-13
Chronic Kidney Disease Registry Platform StudyNCT06117852observationalDisease Progression in CKD Patients—Active, not recruiting—Chronic Kidney Diseases5,0002028-11-30in 833 d2026-08-19
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsNCT06535607Objective response rate (ORR)Randomized · Open-label · TreatmentPhase 2RecruitingBiological: Volrustomig · Drug: Cisplatin, Carboplatin, Paclitaxel, 5-FUSub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)2572028-11-30in 833 d2026-07-06
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in SpainNCT06746116Number of patients with Adverse EventsOpen-label · TreatmentPhase 3Active, not recruitingDrug: Durvalumab + Chemotherapy phase, Durvalumab + Olaparib phaseAdvanced or Recurrent Endometrial Cancer452028-11-30in 833 d2026-07-17
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDerationNCT07052578observationalProportion of patients received any ADT—Recruiting—Prostate Cancer4002028-11-30in 833 d2026-08-18
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379Event-free survival (EFS) in the experimental vs control armsRandomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, OlaparibBreast Cancer1,9022028-11-20in 823 d2026-07-13
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerNCT07218809Progression free Survival (PFS)Randomized · Single-masked · TreatmentPhase 3RecruitingDrug: AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel, Pegylated liposomal Doxorubicin (PLD), TopotecanEpithelial Ovarian Cancer1,1002028-11-17in 820 d2026-07-21
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaNCT06097728Overall Survival (OS) in experimental arm relative to comparator armRandomized · Single-masked · TreatmentPhase 3Active, not recruitingDrug: Volrustomig, Pemetrexed, Carboplatin, Cisplatin, Nivolumab, IpilimumabUnresectable Pleural Mesothelioma8632028-11-16in 819 d2026-07-28
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289Annualized asthma exacerbation rateRandomized · Quadruple-masked · TreatmentPhase 3RecruitingCombination product: ICS-LABA, benralizumab, Placebo for BenralizumabEosinophilic Asthma4002028-11-03in 806 d2026-05-13
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationNCT03833154Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLCRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort) · Other: PlaceboCarcinoma, Non-Small-Cell Lung7242028-10-31in 803 d2026-07-20
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaNCT05951959MRD-negative CR rateOpen-label · TreatmentPhase 2Active, not recruitingDrug: Acalabrutinib, Venetoclax, RituximabMantle Cell Lymphoma (MCL)1082028-10-31in 803 d2026-06-01
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)NCT06960577The safety of neoadjuvant durvalumab combined with ddMVAC or gem/cis prior to radical cystectomy (RC).Open-label · TreatmentPhase 3RecruitingDrug: Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Durvalumab, Gemcitabine, CisplatinUrinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine1502028-10-31in 803 d2026-08-04
MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.NCT07607769observationalTime To Decompensation (TTDec)—RecruitingDrug: STRIDEHepatocellular Carcinoma2002028-10-31in 803 d2026-07-27
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)NCT07064122Number of participants with dose limiting toxicity (DLT)Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: AZD2962Haematologic Neoplasms722028-10-20in 792 d2026-03-02
PRostate Olaparib Real World Evidence StudyNCT06031805observationalTime to treatment discontinuation (TTD)—Recruiting—Metastatic Castration-resistant Prostate Cancer3002028-10-13in 785 d2026-06-02
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).NCT07735637Progression-Free Survival (PFS)Randomized · Open-label · TreatmentPhase 3Not yet recruitingBiological: AZD0120 · Drug: Cyclophosphamide, Fludarabine, Melphalan (part of ASCT), LenalidomideNewly Diagnosed Multiple Myeloma (NDMM)7502028-10-11in 783 d2026-07-30
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsNCT05835310Part A- Anifrolumab serum concentrationRandomized · Quadruple-masked · TreatmentPhase 3RecruitingBiological: Anifrolumab · Drug: PlaceboSystemic Lupus Erythematosus1002028-10-05in 777 d2026-08-14
REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in RomaniaNCT06170671observationalTime to acalabrutinib treatment discontinuation (TTD)—Active, not recruitingDrug: Non interventional studyChronic Lymphocytic Leukemia2502028-09-30in 772 d2026-06-18
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in ChinaNCT07161388observationalrwPFS—Recruiting—Limited Stage Small-Cell Lung Cancer2002028-09-30in 772 d2026-08-04
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.NCT07330245observationalNumber and percentage of patients achieving LLDAS5—RecruitingBiological: AnifrolumabLupus Erythematosus, Systemic2182028-09-30in 772 d2026-07-22
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.NCT07652658To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24Randomized · Quadruple-masked · TreatmentPhase 2RecruitingOther: Placebo for AZD8965 · Drug: AZD8965 low dose, AZD8965 medium dose, AZD8965 high doseIdiopathic Pulmonary Fibrosis (IPF)3592028-09-14in 756 d2026-06-25
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus ErythematosusNCT07751848The proportion of patients who achieve DORIS remission at week 52Open-label · TreatmentPhase 3Not yet recruitingDrug: AnifrolumabLupus Erythematosus, Systemic4172028-08-25in 736 d2026-08-07
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsNCT05797168Number of participants with adverse events/serious adverse eventsRandomized · Open-label · TreatmentPhase 1/2RecruitingDrug: Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, PembrolizumabOvarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma6022028-08-04in 715 d2026-07-23
First in Human Study of AZD9592 in Solid TumorsNCT05647122Incidence of Adverse Events (AEs)Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, BevacizumabAdvanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms1672028-08-03in 714 d2026-06-11
Real-life Treatment Outcomes of Ravulizumab in PNHNCT06633536observationalChange in LDH levels from index date (first dose of ravulizumab) at every 6 month—Active, not recruitingDrug: RavulizumabParoxysmal Nocturnal Haemoglobinuria642028-08-01in 712 d2026-06-12
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMNCT07667803Percent body weight lossRandomized · Triple-masked · TreatmentPhase 3RecruitingDrug: Elecoglipron, PlaceboWeight Management4,5002028-07-31in 711 d2026-07-10
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusNCT07662044Change from baseline in Hemoglobin A1c (HbA1c)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placeboType 2 Diabetes Mellitus8002028-07-14in 694 d2026-08-04
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinNCT07662135Change from baseline in Hemoglobin A1c (HbA1c)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Elecoglipron, PlaceboType 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease9002028-07-13in 693 d2026-08-04
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNCT05211895Progression Free Survival (PFS)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Durvalumab, Domvanalimab · Other: PlaceboNon-Small Cell Lung Cancer8602028-07-12in 692 d2026-06-10
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109Change from baseline in Hemoglobin A1c (HbA1c)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placeboType 2 Diabetes Mellitus2,0002028-07-05in 685 d2026-08-04
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic AlterationsNCT06494540observationalTwo-year real-world overall survival (rwOS) rate of patients with NSQ mNSCLC in the total study population—Recruiting—Non-squamous Metastatic Non-Small-Cell Lung Carcinoma6002028-06-30in 680 d2026-05-22
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus ErythematosusNCT06673043observationalChange from index date in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score—Active, not recruitingDrug: AnifrolumabLupus Erythematosus, Systemic1052028-06-30in 680 d2026-06-16
EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in GreeceNCT06724575observationalChange in the ACQ-6 score at baseline and up to 104 weeks post-index—Active, not recruiting—Asthma1552028-06-30in 680 d2026-06-15
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsNCT07201558Safety evaluation of surovatamig: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs)Non-randomized · Open-label · TreatmentPhase 1RecruitingBiological: SurovatamigRheumatoid Arthritis, Systemic Lupus Erythematosus482028-06-27in 677 d2026-07-29
Danicopan PMS in KoreaNCT07457151observationalSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs/ADRs), AESI—Recruiting—Paroxysmal Nocturnal Hemoglobinuria272028-06-27in 677 d2026-08-14
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaNCT04594642Incidence of subjects with Dose-limiting toxicities (DLT)Open-label · TreatmentPhase 1Active, not recruitingDrug: AZD0486 IVB-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma2262028-06-19in 669 d2026-06-17
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)NCT07391657To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM.Randomized · Open-label · TreatmentPhase 3RecruitingBiological: AZD0120 · Drug: Daratumumab, Carfilzomib, Dexamethasone, Bortezomib, PomalidomideRelapsed Refractory Multiple Myeloma5082028-06-14in 664 d2026-08-06
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerNCT06467357Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomigRandomized · Open-label · TreatmentPhase 3RecruitingDrug: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, RilvegostomigBiliary Tract Cancer6202028-06-12in 662 d2026-08-19
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaNCT06023589Annualized severe asthma exacerbation rate (AAER)Randomized · Triple-masked · TreatmentPhase 3RecruitingBiological: Tezepelumab · Other: PlaceboAsthma2312028-05-31in 650 d2026-08-17
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)NCT07073547Adverse Events (AEs)Open-label · TreatmentPhase 1RecruitingBiological: AZD0120Multiple Myeloma402028-05-26in 645 d2026-07-13
PASS of Paediatric Patients Initiating SelumetinibNCT05388370observationalLVEF reduction—Active, not recruiting—Neurofibromatosis Type 11242028-05-23in 642 d2026-03-12
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213Change from baseline in Hemoglobin A1c (HbA1c)Randomized · Open-label · TreatmentPhase 3RecruitingDrug: Elecoglipron, SemaglutideType 2 Diabetes Mellitus1,2002028-05-23in 642 d2026-07-14
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinNCT07664553Change from baseline in Hemoglobin A1c (HbA1c)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Elecoglipron, PlaceboType 2 Diabetes Mellitus6002028-05-23in 642 d2026-08-04
Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 AgonistNCT07718724Difference in the proportion of participants with a written diagnosis of "Severe Asthma" between the intervention and control groups at Week 24Randomized · Open-label · OtherNot applicableNot yet recruitingBehavioral: Intervention groupUncontrolled Asthma5402028-04-30in 619 d2026-07-22
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic LeukemiaNCT07109219Module 1 (Dose Escalation): Number of participants with dose-limiting toxicities (DLTs).Non-randomized · Open-label · TreatmentPhase 1/2RecruitingCombination product: AZD4512 monotherapyB-cell Acute Lymphoblastic Leukemia (B-ALL)832028-04-28in 617 d2026-07-13
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney DiseaseNCT07571746Number of participants with adverse events.Open-label · TreatmentPhase 2RecruitingDrug: SurovatamigPrimary Membranous Nephropathy432028-04-24in 613 d2026-08-11
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLNCT06526793Overall response rate (ORR) (central review)Non-randomized · Open-label · TreatmentPhase 2RecruitingDrug: SurovatamigB-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)2702028-04-21in 610 d2026-08-13
Human ADME Study of [14C]-AZD1390NCT07643870The mass balance of total Radioactivity of AZD1390 and its metabolites after a single oral doseOpen-label · TreatmentPhase 1Not yet recruitingDrug: AZD1390Advanced Solid Malignancies82028-04-12in 601 d2026-06-12
Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaNCT07088991observationalAge (full years) at the inclusion into the study (date of Visit 1)—Recruiting—Neurofibromatosis2002028-03-31in 589 d2026-07-20
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in RussiaNCT07399665observational1. Change in endoscopic status of CRSwNP based on NPS—Recruiting—Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Asthma1102028-03-31in 589 d2026-08-13
DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR)—RecruitingDrug: Trastuzumab deruxtecanAdenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer1002028-03-30in 588 d2026-07-22
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerNCT06350097To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Progression Free Survival (PFS) by BICR in all randomised participants.Randomized · Open-label · TreatmentPhase 3RecruitingDrug: Osimertinib, Datopotamab DeruxtecanNon-small Cell Lung Cancer5822028-03-21in 579 d2026-05-06
A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)NCT06943833Progression-free Survival at 24 months (PFS24)Open-label · TreatmentPhase 2Active, not recruitingBiological: VolrustomigLocally Advanced Cervical Cancer372028-03-13in 571 d2026-08-18
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaNCT07123454Percentage of participants with dose-limiting toxicities (DLTs)Non-randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD4512B-cell Non-Hodgkin Lymphoma912028-03-01in 559 d2026-06-29
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With TezepelumabNCT07520162To describe changes from baseline in nasal polyp score (NPS)Open-label · TreatmentPhase 3RecruitingDrug: TezepelumabChronic Rhinosinusitis With Nasal Polyps2302028-03-01in 559 d2026-08-14
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCNCT06376084observationalReal-World Progression Free Survival (rwPFS)—Active, not recruiting—Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms5322028-02-28in 557 d2026-08-18
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.NCT06268873To determine whether baxdrostat/dapagliflozin is superior to dapagliflozin alone to slow CKD progression, assessed as the effect on change in eGFR over time.Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Baxdrostat/dapagliflozin, Dapagliflozin in combination with placeboChronic Kidney Disease and Hypertension2,5542028-02-24in 553 d2026-06-26
A Study of AZD0120 in Autoimmune DiseasesNCT07295847Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)Open-label · TreatmentPhase 1RecruitingBiological: AZD0120Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis272028-02-22in 551 d2026-07-28
A Trial to Investigate Benralizumab in Children With Eosinophilic DiseasesNCT06512883Number of Participants with Adverse Events (AEs)Open-label · TreatmentPhase 3RecruitingDrug: BenralizumabEosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)142028-02-20in 549 d2026-07-21
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaNCT06137118Part A: Frequency of DLTsRandomized · Open-label · TreatmentPhase 1/2RecruitingDrug: SurovatamigB-cell Acute Lymphoblastic Leukemia (B-ALL)2552028-02-11in 540 d2026-08-19
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.NCT07686120Change from baseline in ambulatory 24-hour average Systolic blood pressure(SBP) at Week 12Randomized · Quadruple-masked · TreatmentPhase 3Not yet recruitingDrug: baxdrostat 2mg, Placebo 2mgUncontrolled Hypertension2862028-02-09in 538 d2026-07-07
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesNCT05417594Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs)Non-randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd)Advanced Solid Malignancies6952028-02-07in 536 d2026-08-12
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerNCT07205822Progression Free Survival (PFS) per RECIST 1.1 as assessed by the investigatorOpen-label · TreatmentPhase 3RecruitingDrug: Dato-DXdBreast Cancer1002028-02-02in 531 d2026-07-27
REBECCA Real-world Early BrEast CanCer mAnagementNCT06856343observationalProportion of patients who receive Olaparib for the full treatment duration—Recruiting—Breast Cancer1262028-01-31in 529 d2026-07-07
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With BenralizumabNCT06862206observationalasthma control questionnaire—RecruitingOther: benralizumabChronic Obstructive Pulmonary Disease1,0002028-01-30in 528 d2026-07-22
A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa ColonizationNCT07774403Annualized rate of exacerbations over a variable follow-up timeRandomized · Triple-masked · PreventionPhase 2RecruitingDrug: AZD0292 · Other: PlaceboBronchiectasis With Pseudomonas Aeruginosa Colonization842028-01-18in 516 d2026-08-19
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.NCT07357597Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in patients receiving prophylactic dexamethasone mouthwash within first 12 weeks of study treatmentOpen-label · PreventionPhase 4RecruitingDrug: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd)Stomatitis1002028-01-04in 502 d2026-08-05
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome PatientsNCT06099236observationalEvent free survival, where event defined as ESRD or death on or after TMA onset.—Active, not recruiting—Atypical Hemolytic Uremic Syndrome(aHUS)3672027-12-31in 498 d2026-07-22
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World UseNCT06314282observationalPGA—Recruiting—Systemic Lupus Erythematosus (SLE)2002027-12-31in 498 d2026-07-17
A Non-interventional, Prospective Study With BenralizumabNCT06422078observationalChange in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose—Recruiting—Asthma, Bronchial3002027-12-31in 498 d2026-06-24
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainNCT06764186Time to next treatment (TTNT)Open-label · TreatmentPhase 3Active, not recruitingDrug: Fulvestrant, CapivasertibLocally Advanced or Metastatic Breast Cancer1012027-12-31in 498 d2026-07-06
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainNCT07029737Best Overall Response Rate (ORR)Open-label · TreatmentPhase 2RecruitingDrug: Acalabrutinib + R-CHOP standard of care, Acalabrutinib combination with Rituximab, Acalabrutinib monotherapyMantle-cell Lymphoma552027-12-31in 498 d2026-08-03
Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.NCT06417801observationalPrevalence of emerging ESR1 mutations—Recruiting—Metastatic Breast Cancer1702027-12-30in 497 d2026-07-22
A Study in Patients With Myasthenia Gravis in ChinaNCT06700616observationalClinical outcome—Active, not recruiting—Myasthenia Gravis1,1992027-12-30in 497 d2026-06-11
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerNCT07427394Number of participants with adverse events (AEs) and serious AEsOpen-label · TreatmentPhase 2RecruitingDrug: Camizestrant, AtirmociclibAdvanced Breast Cancer242027-12-29in 496 d2026-08-07
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaNCT060848841. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phaseOpen-label · TreatmentPhase 1/2Active, not recruitingBiological: AZD5851Hepatocellular Carcinoma942027-12-13in 480 d2026-08-19
Hyperkalemia Quality Improvement Program (HK-QIP) StudyNCT06884267The proportion of patients who achieve RAASi optimizationa with normal sK+ level (3.5 mmol/L ≤ sK+ ≤5.0 mmol/L) after 48 weeks intervention.Open-label · OtherNot applicableActive, not recruitingOther: standard hyperkalemia management implementationHyperkalemia1,0002027-12-11in 478 d2026-05-08
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa ColonizationNCT07088926Annualized rate of exacerbations over a variable follow-up timeRandomized · Triple-masked · PreventionPhase 2RecruitingBiological: AZD0292 · Other: PlaceboBronchiectasis With Pseudomonas Aeruginosa Colonization4352027-12-09in 476 d2026-08-18
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966Time to first severe cardiac or COPD eventRandomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μgCOPD (Chronic Obstructive Pulmonary Disease)5,2502027-12-03in 470 d2026-06-24
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PNNCT05309668results2025-05-14Selumetinib AUC0-12 Derived After Single Dose AdministrationOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2Active, not recruitingDrug: Selumetinib granule formulation, Selumetinib capsule formulationNeurofibromatosis Type 1362027-11-30in 467 d2026-08-13
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT05702229ORR (per RECIST 1.1 as assessed by Investigator)Non-randomized · Open-label · TreatmentPhase 2RecruitingDrug: Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD0901, 5-Fluorouracil, CapecitabineGastric Cancer1632027-11-30in 467 d2026-05-14
CHARM Hepatocellular Carcinoma MEA StudyNCT07650773observationalPatient Clinical Characteristics—Not yet recruiting—HepatoCellular Carcinoma4,0002027-11-30in 467 d2026-06-16
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) StudyNCT06494241observationalTo evaluate the molecular testing pattern in metastatic NSCLC patients after QIP—Active, not recruiting—Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms1,0002027-11-28in 465 d2026-06-02
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)NCT06079671Progression-free Survival (PFS) based on the investigator assessment in all randomized participants (FAS)Randomized · Quadruple-masked · TreatmentPhase 3RecruitingBiological: Volrustomig · Other: PlaceboLocally Advanced Cervical Cancer8002027-11-26in 463 d2026-07-29
A Study of AZD4063 in PLN R14del Dilated CardiomyopathyNCT07241104Number of participants with adverse events (AEs)Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: AZD4063Dilated Cardiomyopathy312027-11-22in 459 d2026-07-16
Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk PopulationsNCT07338942Proportion of patients diagnosed with ATTR in high-risk population.Open-label · ScreeningNot applicableActive, not recruitingBehavioral: implementation of standard early identification and diagnosis of ATTRATTR-CM4,0002027-11-20in 457 d2026-08-07
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate CancerNCT07529717Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)Randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD8359, AZD8359, AZD8359, AZD8359Metastatic Prostate Cancer422027-11-17in 454 d2026-08-06
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid ArthritisNCT07276581Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12Randomized · Quadruple-masked · TreatmentPhase 2RecruitingDrug: AZD1163 · Other: PlaceboRheumatoid Arthritis3202027-11-12in 449 d2026-06-24
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT07082738Annualised rate of moderate or severe COPD exacerbationsRandomized · Quadruple-masked · TreatmentPhase 2RecruitingDrug: AZD6793 · Other: PlaceboChronic Obstructive Pulmonary Disease (COPD)9872027-11-05in 442 d2026-08-11
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenNCT05624450Proportion of participants who die or progress to Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO)Randomized · Triple-masked · TreatmentPhase 3RecruitingDrug: Tozorakimab, PlaceboViral Lung Infection and Acute Respiratory Failure3,5272027-11-04in 441 d2026-07-21
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaNCT07069712Number of participants with adverse events (AEs) and serious adverse events (SAEs)Non-randomized · Open-label · TreatmentPhase 2RecruitingDrug: Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU), FLOT Chemotherapy, Calcium folinateGastroesophageal Adenocarcinoma1002027-11-03in 440 d2026-08-17
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)NCT04862663Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol.Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Capivasertib, Fulvestrant, Palbociclib, Ribociclib, AbemaciclibLocally Advanced (Inoperable) or Metastatic Breast Cancer8932027-11-01in 438 d2026-08-17
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsNCT05687266Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive populationRandomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, PaclitaxelNSCLC1,3502027-11-01in 438 d2026-04-22
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast CancerNCT06727227observationalReal-world Time to Next Treatment (rwTTNT1, median, 95% CI, measured in months)—RecruitingDrug: trastuzumab deruxtecanBreast Cancer1382027-10-31in 437 d2026-08-17
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy VolunteersNCT06951880Number of participants with adverse events (AEs)Randomized · Single-masked · TreatmentPhase 1Not yet recruitingDrug: AZD4916 · Other: PlaceboHealthy Participants1602027-10-25in 431 d2026-06-15
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese PopulationNCT06724848observationalMedical History—Recruiting—COPD8502027-10-21in 427 d2026-06-02
A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP PatientsNCT07446738observational• The observed and change from baseline of Sino-Nasal Outcome Test (SNOT)-22 score at week-52—RecruitingProcedure: Endoscopic Sinus Surgery (ESS)Chronic Rhinosinusitis With Nasal Polyps2002027-10-21in 427 d2026-08-14
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)NCT07044336Progression Free Survival (PFS) for Arm A vs Arm BRandomized · Single-masked · TreatmentPhase 3RecruitingDrug: Puxitatug Samrotecan, Doxorubicin, PaclitaxelEndometrial Cancer, Malignant Solid Tumour8002027-10-15in 421 d2026-07-29
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerNCT07402915Area under curve from time 0 to time 17 days (AUC0-17days)Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: AZD5335, ItraconazoleFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal242027-10-15in 421 d2026-07-07
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaNCT06307665Annualized rate of severe asthma exacerbations (AAER)Randomized · Double-masked · TreatmentPhase 3RecruitingCombination product: BDA MDI, AS MDIAsthma4402027-10-13in 419 d2026-08-13
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With AsthmaNCT06471257Time to first severe asthma exacerbationRandomized · Double-masked · TreatmentPhase 3RecruitingCombination product: Budesonide/Albuterol metered dose inhaler, MDI, Albuterol sulfate metered dose inhaler, MDIAsthma1,0002027-10-04in 410 d2026-08-07
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211Objective response rate (ORR)Non-randomized · Open-label · TreatmentPhase 2RecruitingDrug: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, CisplatinEndometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer4542027-10-01in 407 d2026-08-13
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsNCT05801029Number of participants with adverse events (AEs)Open-label · TreatmentPhase 2Active, not recruitingDrug: Osimertinib, AmivantamabNon-Small Cell Lung Cancer (NSCLC)602027-10-01in 407 d2026-06-12
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)NCT05850234Phase 1b: Adverse Events (AEs)Open-label · TreatmentPhase 1/2RecruitingBiological: AZD0120Relapsed/Refractory Multiple Myeloma2322027-10-01in 407 d2026-08-17
A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiANCT05939128observationalThe primary objective of this study is to determine the prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer—Active, not recruiting—Breast Cancer6252027-09-30in 406 d2026-05-15
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491Radiographic Progression-Free Survival (rPFS)Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Saruparib, Placebo, Abiraterone Acetate, Darolutamide, EnzalutamideMetastatic Castration-Sensitive Prostate Cancer1,8982027-09-30in 406 d2026-07-29
Study That Will Evaluate the Brazilian Population With COPD.NCT06780046observationalIncidence of hospitalizations—Recruiting—COPD (Chronic Obstructive Pulmonary Disease)6932027-09-30in 406 d2026-08-13
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/TrixeoNCT07069829observationalchange from baseline in the COPD Assessment Test—Recruiting—Chronic Obstructive Pulmonary Disease1,4002027-09-30in 406 d2026-06-29
LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in CanadaNCT07143110observationalTreatment patterns—Recruiting—Lung Neoplasms60,0002027-09-30in 406 d2026-07-09
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesNCT05123482The number of patients with adverse eventsRandomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer4602027-09-29in 405 d2026-08-12
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585Invasive disease-free survival (iDFS) for Dato-DXd + durvalumab vs. ICTRandomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Dato-DXd, Durvalumab, Capecitabine, PembrolizumabBreast Cancer1,1742027-09-20in 396 d2026-06-15
A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese AdultsNCT07612813Occurrence of Adverse Events (AEs)Randomized · Double-masked · PreventionPhase 1RecruitingDrug: AZD7760 · Other: PlaceboStaphylococcus Aureus Bloodstream Infection182027-09-13in 389 d2026-08-18
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersNCT06594068Area under the milk concentration-time curve during a dosing intervalOpen-label · TreatmentPhase 4RecruitingDrug: AnifrolumabSystemic Lupus Erythematosus162027-08-31in 376 d2026-08-18
Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial IntelligenceNCT07617636observationalLung cancer risk stratification—Not yet recruiting—Lung Cancer1,5002027-08-31in 376 d2026-06-29
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914Part A (Dose Escalation): Evaluate the safety of KRAS TCRTs in subjects with unresectable, advanced, and/or metastatic solid tumorsNon-randomized · Open-label · TreatmentPhase 1RecruitingBiological: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12DNon-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D1082027-08-30in 375 d2026-07-28
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney DiseaseNCT06824987Relative change in Urine Albumin-Creatinine Ratio (UACR)Randomized · Quadruple-masked · TreatmentPhase 2RecruitingCombination product: AZD2373-Arm 1, AZD2373-Arm 2, Placebo · Device: APOL1 Genotyping Clinical Trial AssayAPOL1-Mediated Kidney Disease1362027-08-30in 375 d2026-06-25
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabNCT07391670Area under the concentration-time curveRandomized · Open-label · TreatmentPhase 1RecruitingDrug: SC durvalumab + rHu, IV durvalumab, TremelimumabSolid Tumours402027-08-30in 375 d2026-07-13
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaNCT06106945Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)Open-label · TreatmentPhase 1/2RecruitingDrug: AZD0305, Elranatamab, Pomalidomide, DexamethasoneMultiple Myeloma2262027-08-16in 361 d2026-08-19
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary AldosteronismNCT07007793Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8Randomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: Baxdrostat, PlaceboPrimary Hyperaldosteronism2502027-08-13in 358 d2026-07-06
Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabNCT07363642To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in the overall patient population while maintaining asthma controlOpen-label · TreatmentPhase 3RecruitingDrug: TezepelumabSevere Asthma4002027-08-07in 352 d2026-06-25
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsNCT06188520Incidence of dose limiting toxicities (DLTs) as defined in the protocol.Non-randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD8421, Camizestrant, Ribociclib, Palbociclib, AbemaciclibER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)5642027-08-04in 349 d2026-08-06
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionNCT05120349Disease-Free Survival (DFS) in high-risk stratumRandomized · Triple-masked · TreatmentPhase 3Active, not recruitingDrug: Osimertinib, PlaceboNon-Small Cell Lung Cancer3902027-08-02in 347 d2026-07-06
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREANCT07570394observationalIncidence proportion of Adverse Events (AEs)/Adverse Drug Reactions (ADRs)—Not yet recruiting—Chronic Obstructive Pulmonary Disease (COPD)6002027-07-31in 345 d2026-05-06
Volrustomig Priming Regimens Exploratory Phase II Platform StudyNCT06448754Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Open-label · TreatmentPhase 2RecruitingDrug: Volrustomig, Carboplatin, Pemetrexed, Ramucirumab, PaclitaxelNon-small Cell Lung Cancer1802027-07-30in 344 d2026-08-10
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.NCT07619131Relative change in LDL-C at 8 weeksRandomized · Quadruple-masked · TreatmentPhase 3Not yet recruitingDrug: Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Placebo to match rosuvastatin, Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Placebo to match Laroprovstat/Rosuvastatin 2Hypercholesterolaemia6002027-07-30in 344 d2026-06-01
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBENCT07245407observationalFEV1/FVC%—RecruitingOther: Participant Follow-upNon-cystic Fibrosis Bronchiectasis3202027-07-29in 343 d2026-07-14
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)NCT06103864Progression Free Survival (PFS)Randomized · Open-label · TreatmentPhase 3RecruitingDrug: Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, PembrolizumabBreast Cancer6252027-07-28in 342 d2026-07-20
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care TherapyNCT07161414Area under the Concentration-time Curve During One Dosing Interval (AUCtau)Randomized · Open-label · TreatmentPhase 1RecruitingDrug: IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig, SC rilvegostomig + rHuAdvanced Solid Tumors402027-07-19in 333 d2026-08-10
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid TumorsNCT06005493The number of patients with adverse eventsRandomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD5863Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma2802027-07-16in 330 d2026-02-24
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT05057494Progression-free Survival (PFS)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Acalabrutinib, Venetoclax, ObinutuzumabChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma6072027-07-15in 329 d2026-05-19
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or ObesityNCT07013643Area under the concentration-time curve from time 0 to infinity (AUCinf) of EE and LEVONon-randomized · Open-label · TreatmentPhase 1RecruitingDrug: AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550Healthy Participants502027-07-09in 323 d2026-08-18
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced FibrosisNCT07610837Absolute change in Enhanced Liver Fibrosis (ELF) score from baseline to week 24Randomized · Double-masked · TreatmentPhase 2RecruitingDrug: AZD2389 · Other: PlaceboLiver Fibrosis, Hepatic Cirrhosis1042027-07-07in 321 d2026-07-29
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCNCT04550260Progression free survival (PFS) per RECIST 1.1 as assessed by BICRRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine · RadiationEsophageal Squamous Cell Carcinoma6402027-06-30in 314 d2026-05-13
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCNCT04686305Frequency of AEs and SAEsRandomized · Open-label · TreatmentPhase 1RecruitingDrug: T-DXd, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig · Biological: DurvalumabLocally Advanced or Metastatic Non-Small Cell Lung Cancer3042027-06-30in 314 d2026-04-13
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)NCT06472310observationalTo characterise the profile of routine therapy used for patients with uncontrolled SA not receiving biological therapy in proportion of patients receiving different classes of drugs will be calculated—Recruiting—Severe Asthma5,0002027-06-30in 314 d2026-06-24
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesNCT06564844Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoCRandomized · Single-masked · TreatmentPhase 3Active, not recruitingDrug: Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFTNon-small Cell Lung Cancer252027-06-30in 314 d2026-08-18
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in GermanyNCT06675552observationalProportion of patients treated with HFrEF GDMT—Recruiting—Heart Disease, Heart Failure, Cardiovascular Disease, Heart Failure, Systolic4382027-06-30in 314 d2026-07-14
A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerNCT06792695Progression Free Survival (PFS)Randomized · Open-label · TreatmentPhase 2RecruitingDrug: Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), BevacizumabMetastatic Colorectal Cancer802027-06-30in 314 d2026-08-18
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid TumoursNCT06795022The number of patients with adverse eventsNon-randomized · Open-label · TreatmentPhase 1/2RecruitingDrug: AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapyHepatocellular Carcinoma3042027-06-30in 314 d2026-08-13
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian FederationNCT07041606observationalThe rate of POLEm positive status—Recruiting—Endometrial Cancer5002027-06-30in 314 d2026-08-10
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of HistologyNCT07167433observationalDescription of socio-demographic characteristics—Recruiting—Ovarian Cancer2502027-06-30in 314 d2026-08-04
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in RussiaNCT07390240observational(1) Mean age (in full years) at the HPP diagnosis;—Recruiting—Hypophosphatasia552027-06-30in 314 d2026-07-20
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.NCT06473779Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase.Randomized · Open-label · TreatmentPhase 3Active, not recruitingCombination product: Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, SalbutamolSevere Asthma3262027-06-25in 309 d2026-06-15
Study of Patient With Frequent Exacerbations in MoscowNCT07307781observationalTo describe the baseline mean age of outpatients with COPD in Moscow.—Recruiting—Chronic Obstructive Pulmonary Disease (COPD)5002027-06-25in 309 d2026-05-29
TROP2 NMR Concordance StudyNCT07624318observationalStage 1 - Solution concordance in central lab: To evaluate TROP2 NMR concordance between Local solution and Reference solution in the central lab—Not yet recruitingDevice: Reference solution, Mixed solution, Local solutionLung Cancer3,4002027-06-15in 299 d2026-06-15
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652Time to first occurrence of any of the components of the composite of: •CV death •HF hospitalisation •HF event without hospitalisationRandomized · Quadruple-masked · TreatmentPhase 3RecruitingDrug: balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozinHeart Failure and Impaired Kidney Function4,8002027-06-11in 295 d2026-06-26
Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma DiagnosisNCT07516184To explore the diagnostic value of portable oscillometry in suspected asthma patientsOpen-label · DiagnosticNot applicableRecruitingDevice: Pulmonary function Test interventionSuspected Asthma5002027-06-11in 295 d2026-06-23
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsNCT06932263Annualised rate of severe asthma exacerbationsRandomized · Quadruple-masked · TreatmentPhase 2RecruitingDrug: Tozorakimab, PlaceboAsthma5402027-06-07in 291 d2026-07-20
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CMNCT07690436observationalComparison of per-participant confidence scores distributions between ATTR-CM cases and HF controls without ATTR-CM—Not yet recruiting—Transthyretin Amyloid Cardiomyopathy5002027-06-03in 287 d2026-07-08
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)NCT04379596Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0Randomized · Open-label · TreatmentPhase 2RecruitingDrug: Fluorouracil (5-FU), Capecitabine, Oxaliplatin, Trastuzumab deruxtecan, Cisplatin · Biological: Durvalumab, Trastuzumab, Pembrolizumab, Volrustomig, RilvegostomigGastric Cancer4502027-06-01in 285 d2026-07-10
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney DiseaseNCT06610526Time to the first occurrence of any of the components of the composite: 50% sustained decline in eGFR or Reaching ESRD or CV Death or Renal Death.Non-randomized · Open-label · TreatmentPhase 4Active, not recruitingDrug: DapagliflozinChronic Kidney Disease7312027-05-31in 284 d2026-01-30
Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast CancerNCT06827132observationalprimary objective—Active, not recruiting—Lung Cancer, Breast Cancer6002027-05-31in 284 d2026-06-01
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and HyperinflationNCT07073950Change from baseline in left ventricular end diastolic volume indexed by body surface area (LVEDVi) measured by magnetic resonance imaging (MRI)Randomized · Double-masked · TreatmentPhase 4RecruitingDrug: Budesonide/Glycopyrronium/Formoterol Fumarate, Placebo · Device: Metered dose inhalerChronic Obstructive Pulmonary Disease, Hyperinflation562027-05-31in 284 d2026-07-24
Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNsNCT06175637observationalNF1-PN patient demographics and disease characteristics at baseline and during selumetinib treatment—Active, not recruiting—Neurofibroma, Plexiform4092027-05-30in 283 d2026-08-13
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in ItalyNCT06948396observationalDemographic and Clinic characterization—Active, not recruitingBiological: TezepelumabAsthma3152027-05-30in 283 d2026-07-20
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse eventsNon-randomized · Open-label · TreatmentPhase 1/2Active, not recruitingDrug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, CamizestrantOvarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 57022027-05-28in 281 d2026-08-19
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With HypercholesterolaemiaNCT07619118Relative change in LDL-C at 8 weeksRandomized · Quadruple-masked · TreatmentPhase 3Not yet recruitingCombination product: laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3, laroprovstat/rosuvastatin 4 · Drug: Placebo to match laroprovstat/rosuvastatin 1,2,3, Placebo to match laroprovstat/rosuvastatin 4, Rosuvastatin 1, Rosuvastatin 2, Rosuvastatin 3, Rosuvastatin 4, Placebo to match RosuvastatinHypercholesterolaemia2002027-05-28in 281 d2026-06-01
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.NCT07222917To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria.Randomized · Quadruple-masked · TreatmentPhase 2RecruitingDrug: Baxdrostat/dapagliflozin, Baxdrostat/PlaceboChronic Kidney Disease and Hypertension2182027-05-24in 277 d2026-05-18
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney DiseaseNCT07228364Incidence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentPhase 1RecruitingDrug: AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B, Placebo - Part BAutosomal Dominant Polycystic Kidney Disease402027-05-22in 275 d2026-07-28
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)NCT06455449Total Improvement Score (TIS) ≥ 40 responseRandomized · Quadruple-masked · TreatmentPhase 3RecruitingCombination product: Anifrolumab (blinded), Anifrolumab (unblinded, open label) · Other: PlaceboPolymyositis, Dermatomyositis2402027-05-14in 267 d2026-05-28
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.NCT06916806Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events.Non-randomized · Open-label · TreatmentPhase 1RecruitingDrug: AZD5492Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis722027-05-05in 258 d2026-07-23
Acalabrutinib Real World Italian obSErvational Study -ARISENCT06205498observationaltime to acalabrutinib discontinuation—Active, not recruitingDrug: acalabrutinibChronic Lymphocytic Leukemia1512027-04-30in 253 d2026-04-23
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment PatternsNCT07109154observationalDescribe epidemiological characteristics of patients diagnosed with NSCLC in Brazil real-world.—Recruiting—Lung Neoplasms2002027-04-30in 253 d2026-05-13
Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist DiagnosisNCT07245576observationalAccuracy of primary care asthma/COPD diagnosis using oscillometry (ALDS: R5, R20, R5-R20, X5, Ax) plus FeNO ≥50 ppb (Fenom PRO®/ALDS Pro) vs specialist gold standard; metrics: Cohen's kappa, agreement, sensitivity, specificity in overall, asthma, COPD—Recruiting—Asthma, COPD6002027-04-30in 253 d2026-05-27
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951Invasive breast cancer-free survival (IBCFS)Randomized · Open-label · TreatmentPhase 3RecruitingDrug: Camizestrant, Tamoxifen, Anastrozole, Letrozole, ExemestaneBreast Cancer, Early Breast Cancer4,3002027-04-20in 243 d2026-08-19
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal AntibodyNCT07285213First occurrence of recurrence of C difficile infectionRandomized · Quadruple-masked · PreventionPhase 2RecruitingDrug: AZD5148 · Other: PlaceboClostridioides Difficile Infection2302027-04-20in 243 d2026-08-12
An Ophthalmic Safety Study in Patients With Breast CancerNCT06767462observationalVisual Acuity Testing (Snellen units)—Active, not recruiting—Ophthalmic Safety in Patients With Breast Cancer1602027-04-09in 232 d2026-06-16
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.NCT07511205Number of participants with adverse events (AEs), serious adverse events (SAEs), AE leading to discontinuation (DAEs), and AEs of special interest (AESIs)Randomized · Triple-masked · TreatmentPhase 1RecruitingDrug: AZD1043 · Other: PlaceboHealthy Participants, Obesity1042027-04-09in 232 d2026-08-10
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibNCT04421963Safety follow upOpen-label · TreatmentPhase 3Active, not recruitingDrug: OlaparibOvarian Cancer, Breast Cancer1852027-04-06in 229 d2026-06-12
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)NCT06749457Phase I: Occurence of adverse events (AEs)Randomized · Quadruple-masked · PreventionPhase 1/2RecruitingDrug: AZD7760 · Other: PlaceboStaphylococcus Aureus2312027-04-02in 225 d2026-08-14
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United KingdomNCT05557695observationalReal-world progression free survival (rwPFS)—RecruitingDrug: AcalabrutinibChronic Lymphocytic Leukemia, CLL3502027-04-01in 224 d2026-06-02
CLL Therapy Approaches in RussiaNCT05140369observationalSex—Active, not recruiting—Chronic Lymphocytic Leukemia6,0002027-03-31in 223 d2026-05-14
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)NCT05141201observationalIncidence of ADRs—Active, not recruiting—Lupus Erythematosus, Systemic1,6202027-03-31in 223 d2026-06-17
Study for AZD4360 in Participants With Advanced Solid TumoursNCT06921928Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360Open-label · TreatmentPhase 1/2Active, not recruitingDrug: AZD4360Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma312027-03-31in 223 d2026-07-31
PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian CohortNCT07560215observationalprevalence of HRR mutations in tissue and/or liquid biopsy samples—Not yet recruitingDiagnostic test: Archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling.Metastatic Prostate Cancer1002027-03-31in 223 d2026-05-01
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical StudiesNCT07606066observationalPatient demographics—RecruitingOther: Procedure: assessmentType 2 Diabetes2,1502027-03-31in 223 d2026-07-07
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)NCT07613424OPA/PPA/NPANon-randomized · Open-label · Basic scienceNot applicableRecruitingDiagnostic test: NGS testing, MET IHC testing, PD-L1 and Her2 testingNon-Small Cell Lung Cancer1,0002027-03-31in 223 d2026-07-14
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsNCT04482309Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentPhase 2Active, not recruitingDrug: Trastuzumab deruxtecanPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer4772027-03-23in 215 d2026-07-10
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.NCT05683977observationalThe time to first line treatment discontinuation (TTD).—Active, not recruitingDrug: durvalumabSmall Cell Lung Carcinoma2542027-03-01in 193 d2026-06-16
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) DiseaseNCT06851806To assess the safety of palivizumab prophylaxis when administered to preterm infants (≤ 35 wGA), children with BPD (< 24 months) and/or children with haemodynamically significant CHD (< 24 months).Open-label · PreventionNot applicableRecruitingDrug: Palivizumab 15 mg/kgRespiratory Syncytial Virus (RSV)1382027-02-28in 192 d2026-07-09
Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components.NCT06899633observationalProportion of patients with varying SLE activity assessed by the SLEDAI 2K Activity Index at visits 0, 1, and 2—Active, not recruiting—Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan, Description of the Course of SLE in Patients in the Republic of Kazakhstan, Description of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan5092027-02-28in 192 d2026-06-15
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisNCT05138133Difference in proportion of participants with CRR (Complete Renal Response) in anifrolumab group compared with placebo groupRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Anifrolumab, PlaceboLupus Nephritis3632027-02-23in 187 d2026-07-31
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)NCT05629234Number of patients with Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)Open-label · TreatmentPhase 3Active, not recruitingDrug: OsimertinibCancer372027-02-22in 186 d2026-07-09
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaNCT06834932AZD0780 Concentrations in plasma (PART A)Randomized · Triple-masked · TreatmentPhase 2/3Active, not recruitingDrug: Placebo, Rosuvastatin Dose 1, Rosuvastatin dose 2, AZD0780Dyslipidaemia4322027-02-22in 186 d2026-05-11
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)NCT06087835Change in eGFR from baselineRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Zibotentan/Dapagliflozin, DapagliflozinChronic Kidney Disease With High Proteinuria1,8352027-02-18in 182 d2026-08-19
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)NCT06380738observationalTime to treatment discontinuation—Recruiting—Metastatic Castration-resistant Prostate Cancer2502027-02-14in 178 d2026-07-17
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.NCT07215702Area Under the Curve (AUC) of 24-hour Creatinine Clearance (CrCl).Randomized · Triple-masked · TreatmentPhase 2RecruitingDrug: AZD4144, PlaceboSepsis, Acute Kidney Injury1242027-02-11in 175 d2026-07-30
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234NCT07546760PK parameters AUCinfNon-randomized · Open-label · OtherPhase 1RecruitingDrug: AZD6234, AZD9550Hepatic Impairment282027-02-04in 168 d2026-08-04
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine CareNCT06422689Asthma exacerbationOpen-label · TreatmentPhase 4Active, not recruitingDrug: Albuterol and budesonide inhalation aerosolAsthma1,5112027-02-03in 167 d2026-07-16
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA RegionNCT07065344observationalTo describe the treatment patterns for the first line and subsequent therapies for DLBCL patients—Recruiting—Hematology, Diffused Large B Cell Lymphoma5002027-01-31in 164 d2026-06-18
Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)NCT07279948observational• Proportion of negative cases on screening according to the Lung-RADS classification.—Not yet recruiting—Lung Cancer4772027-01-31in 164 d2026-08-03
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightNCT06151964Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study.Randomized · Triple-masked · TreatmentPhase 1/2Active, not recruitingDrug: AZD9550, placebo, AZD9550 and AZD6234Overweight and Obesity1662027-01-29in 162 d2026-06-23
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCNCT07000149Number of participants with adverse events (AEs) and serious adverse events (SAEs)Randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Volrustomig, CasdatifanAdvanced Clear Cell Renal Cell Carcinoma92027-01-29in 162 d2026-08-03
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCNCT05374603PFSOpen-label · TreatmentPhase 2Active, not recruitingDrug: Savolitinib, DurvalumabLung Cancer472027-01-18in 151 d2026-05-14
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With TezepelumabNCT06706817Change from baseline in nasal congestionOpen-label · TreatmentPhase 3Active, not recruitingCombination product: TezepelumabChronic Rhinosinusitis With Nasal Polyps1812027-01-13in 146 d2026-08-05
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventNCT07000123Relative change in LDL-C from baseline to 12 weeksRandomized · Triple-masked · TreatmentPhase 3Active, not recruitingDrug: AZD0780, PlaceboCardiovascular Disease3,1032027-01-11in 144 d2026-08-11
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)NCT05925803Number of participants responding to treatment based on the Revised Composite Response Index in Systemic Sclerosis (CRISS-25)Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingCombination product: Anifrolumab (blinded), Anifrolumab (unblinded, open label) · Drug: Placebo (blinded)Systemic Sclerosis, Scleroderma3142027-01-06in 139 d2026-07-23
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHNCT07000136Relative change in LDL-C from baseline to 12 weeksRandomized · Triple-masked · TreatmentPhase 3Active, not recruitingDrug: AZD0780, PlaceboHeterozygous Familial Hypercholesterolaemia4732027-01-04in 137 d2026-07-16
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabNCT05303532Number of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0Open-label · TreatmentPhase 3Enrolling by invitationDrug: DurvalumabCancer2142026-12-31in 133 d2026-08-11
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma132026-12-31in 133 d2026-07-07
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in GermanyNCT06336330observationalTime to discontinuation of dapagliflozin—Active, not recruiting—Heart Diseases, Cardiovascular Diseases, Heart Failure8312026-12-31in 133 d2026-07-13
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in BrazilNCT06491862observationalDescribe the patient population and treatment patterns—Recruiting—Non-squamous Non-Small Cell Lung Cancer2502026-12-31in 133 d2026-07-22
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON DatabaseNCT06548152observationalTo measure QoL score of CLL patients treated with acalabrutinib, from treatment initiation and up to 12 months—Recruiting—Chronic Lymphocytic Leukemia1202026-12-31in 133 d2026-07-13
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian FederationNCT07038928observationalProportion of patients receiving any intravesical treatment among patients with high-risk NMIBC—Recruiting—Bladder Cancer6002026-12-31in 133 d2026-08-10
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor PatientsNCT07404202observationalNPA of HER2 IHC 3+ based on confusion matrix results betwee other assays(Roche 4B5\MXB\Zhongshan\An Biping\Amoy) and HercepTest—Recruiting—Pan-tumor(NSCLC, GYN Cancers, BTC and UC)2,1002026-12-31in 133 d2026-08-11
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional CohortNCT07024823Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · TreatmentPhase 1RecruitingDrug: AZD4248, Placebo, AZD4248, PlaceboChronic Kidney Disease1242026-12-25in 127 d2026-08-12
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care SettingNCT06712563observationalCOPD Assessment Test (CAT)—Active, not recruitingDrug: Budesonide/glycopyrrolate/formoterol fumaratePulmonary Disease, Chronic Obstructive2,0002026-12-14in 116 d2026-07-22
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.NCT05817110observationalTo estimate the positive and negative predictive values of qXR LNMS (lung nodule malignancy score ) in a multi-centre real-world setting.—Active, not recruitingOther: Participant CohortLung Malignancy7122026-12-06in 108 d2026-05-22
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With DyslipidemiaNCT06980428Part A: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Triple-masked · TreatmentPhase 1RecruitingDrug: AZD4954, PlaceboHealthy Participants, Dyslipidemia1362026-12-04in 106 d2026-07-13
Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/DapagliflozinNCT07754331PK parameters AUCinfRandomized · Open-label · TreatmentPhase 1Not yet recruitingDrug: Balcinrenone/dapagliflozinKidney Failure102026-12-02in 104 d2026-08-10
A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in RussiaNCT05456867observationalSafety of durvalumab in patients with unresectable locally advanced NSCLC without progression after CRT in routine practice of the Russian Federation.—Active, not recruiting—NSCLC, Non-small-cell Lung Carcinoma2502026-11-30in 102 d2026-03-17
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaNCT07081633Progression free survival (PFS) per RECIST 1.1Open-label · TreatmentPhase 2Active, not recruitingDrug: Durvalumab, Tremelimumab · Combination product: LenvatinibHepatocellular Carcinoma1142026-11-30in 102 d2026-05-12
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)NCT07218172observationalAsthma related characteristics—Active, not recruiting—Severe Asthma1972026-11-30in 102 d2026-06-15
Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.NCT06376097observationalAbsolute number and frequency of false-negative lung nodules .—Recruiting—Lung Cancer1,0002026-11-29in 101 d2026-08-03
Study of AZD0754 in Participants With Metastatic Prostate CancerNCT06267729Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs).Non-randomized · Open-label · TreatmentPhase 1/2RecruitingBiological: AZD0754, AZD2287Metastatic Prostate Cancer602026-11-24in 96 d2026-02-23
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy ParticipantsNCT07723833Maximum observed drug concentration (Cmax)Randomized · Open-label · TreatmentPhase 1RecruitingDrug: Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose BHealthy Participants1522026-11-18in 90 d2026-08-03
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.Randomized · Open-label · TreatmentPhase 2RecruitingDrug: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, GemcitabineGastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma2262026-11-17in 89 d2026-07-29
National Acalabrutinib Observational StudyNCT05437250observationalTime to Discontinuation—Active, not recruitingDrug: Non interventional studyChronic Lymphocytic Leukemia3502026-11-15in 87 d2026-05-28
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessmentRandomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, TrastuzumabBreast Cancer; HER2-positive; Metastatic1,1572026-11-11in 83 d2026-07-30
GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian CohortNCT07101081observationalHER2 IHC status as per Dako HercepTest and gastric cancer scoring criteria.—RecruitingDiagnostic test: HER-2 TestGynaecological Cancers3502026-11-11in 83 d2026-07-22
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentNCT07343960Area under concentration time curve from zero to infinity (AUCinf)Non-randomized · Open-label · Basic sciencePhase 1RecruitingDrug: CapivasertibModerate Hepatic Impairment202026-11-11in 83 d2026-07-02
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusNCT06015737Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) scoreRandomized · Double-masked · TreatmentPhase 3Active, not recruitingCombination product: Anifrolumab · Other: PlaceboCutaneous Lupus Erythematosus3392026-11-02in 74 d2026-07-29
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR AmyloidosisNCT06355934observationalHealth Care Resource Utilization (HCRU) - Outpatient visits—RecruitingOther: no interventionATTR Amyloidosis52,1212026-11-02in 74 d2026-08-11
Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)NCT05454787observationalIncidence of adverse drug reactions, Incidence of safety specifications, Incidence of adverse drug reactions by patient background factor—Recruiting—Life Threatening Bleeding, Factor Xa Inhibitor3002026-10-31in 72 d2026-07-28
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian PatientsNCT06429761To assess the safety of trastuzumab deruxtecan in adult Indian patientsOpen-label · TreatmentPhase 4RecruitingDrug: Trastuzumab deruxtecanBREAST CANCER1002026-10-31in 72 d2025-11-24
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447Time to first subsequent treatment (TFST) of PIK3CA/AKT1/PTEN-altered population in Cohort 1Non-randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Capivasertib, FulvestrantBreast Cancer2932026-10-31in 72 d2026-08-17
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary DiseaseNCT06531798To observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPDOpen-label · TreatmentPhase 4RecruitingDrug: Breztri AerosphereModerate to Severe COPD1502026-10-30in 71 d2026-07-22
The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-managementNCT06909773The number and percentage of COPD in participants with CVD,CHD,AF,CHF.Open-label · DiagnosticNot applicableRecruitingBehavioral: Guideline education and implementation interventionCardiovascular Diseases3,0002026-10-28in 69 d2026-06-26
Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy ParticipantsNCT07685600Area under concentration time curve from time 0 to infinity (AUCinf)Randomized · Open-label · TreatmentPhase 1Not yet recruitingDrug: AZD4144, AZD4144, ItraconazoleHealthy322026-10-28in 69 d2026-07-06
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerNCT05775159Objective response rate (ORR)Non-randomized · Open-label · TreatmentPhase 2Active, not recruitingDrug: Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, CisplatinHepatocellular Carcinoma, Biliary Tract Cancer2942026-10-27in 68 d2026-07-02
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASNCT06008093Progression-free survival (PFS) in randomized participantsRandomized · Open-label · TreatmentPhase 2Active, not recruitingDrug: Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, CisplatinCarcinoma, Non-Small-Cell Lung1032026-10-23in 64 d2026-07-02
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy ParticipantsNCT07290283Number of participants with adverse events (AEs) and serious adverse events (SAEs)Randomized · Single-masked · TreatmentPhase 1RecruitingDrug: AZD3974 · Other: PlaceboHealthy Participants1762026-10-21in 62 d2026-07-31
Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsNCT03953300The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsiesRandomized · Triple-masked · TreatmentPhase 4Active, not recruitingBiological: Benralizumab, PlaceboAsthma752026-10-19in 60 d2026-07-28
Retention Rate of Acalabrutinib in a Non-interventional SettingNCT05645172observationalRetention rate of CLL—Active, not recruiting—Chronic Lymphocytic Leukaemia (CLL)1372026-10-15in 56 d2025-12-01
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)NCT07717840Incidence of immediate unsolicited adverse events (AEs)Randomized · Quadruple-masked · PreventionPhase 1/2RecruitingBiological: AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2RSV Respiratory Syncytial Virus1602026-10-15in 56 d2026-07-21
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese PopulationNCT06419413observationalDescriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables.—Recruiting—Asthma3552026-10-08in 49 d2026-08-18
AZD5305 hADME in Patients With Advanced Solid MalignanciesNCT06713369Absolute bioavailability (F) of SaruparibNon-randomized · Open-label · Basic sciencePhase 1RecruitingDrug: Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose)Locally Advanced or Metastatic Solid Tumor82026-10-02in 43 d2026-06-24
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsNCT05663515observationalIncidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population—RecruitingDrug: Exenatide, Non-GLP-1 RA based glucose lowering drugsPancreatic Cancer24,0002026-10-01in 42 d2026-08-04
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840Progression Free Surival (PFS)Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, Oleclumab, Monalizumab · Other: PlaceboNon-Small Cell Lung Cancer1,0512026-09-30in 41 d2026-06-18
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCNCT05557838≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1Non-randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, TremelimumabHepatocellular Carcinoma2142026-09-30in 41 d2026-06-26
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814Progression free Survival (PFS)Randomized · Open-label · TreatmentPhase 3RecruitingDrug: Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, CisplatinMetastatic Non-small Cell Lung Cancer7442026-09-30in 41 d2026-05-14
Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry StudyNCT06521229observationalTo describe the baseline demographic characteristics of outpatients with uncontrolled asthma in the Russian Federation in all patients and in the cohort of patients receiving fixed-dose combination (FDC) budesonide/salbutamol on Visit 2—Recruiting—Uncontrolled Asthma9,0002026-09-30in 41 d2026-04-20
Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in RussiaNCT06566885observationalChange in ACQ-5 score from baseline—Active, not recruiting—Severe Asthma1252026-09-30in 41 d2026-05-12
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma PatientsNCT06605885observationalthe proportion of days covered (PDC) with asthma biologics during 52 weeks—Active, not recruiting—Asthma2022026-09-30in 41 d2026-08-12
A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With DyslipidaemiaNCT07218900Relative change in Low-density lipoprotein cholesterol (LDL-C) from baseline to 12 weeksRandomized · Quadruple-masked · TreatmentPhase 2Active, not recruitingDrug: Placebo, AZD0780, RosuvastatinDyslipidaemia762026-09-30in 41 d2026-06-04
Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)NCT07221331observationalPrevalence of patients with Neurofibromatosis type 1-Plexiform Neurofibromas—Recruiting—Neurofibromatosis Type 12002026-09-30in 41 d2026-08-12
Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology ClinicsNCT07315958observationalPrevalence (number and percentage) of outpatients attending cardiology clinics, with a history of smoking who exhibit concurrent AL consistent with COPD.—Recruiting—Respiratory (Chronic Obstructive Pulmonary Disease)1,0002026-09-30in 41 d2026-08-14
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in BrazilNCT07370194observationalPrevalence of Hyperkalemia—Recruiting—Hyperkalemia6,2152026-09-30in 41 d2026-07-24
HER2-positive Metastatic Breast Cancer in KazakhstanNCT07593196observational(1) To assess median PFS and PFS rate in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan—Not yet recruiting—Metastatic Breast Cancer2402026-09-30in 41 d2026-05-18
A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2NCT07143604Objective Response Rate (ORR)Open-label · TreatmentPhase 2Active, not recruitingDrug: AZD0901Gastric Cancer, Gastroesophageal Junction Cancer332026-09-28in 39 d2026-06-17
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.NCT06995820Number of participants with adverse events (AEs) and serious AEs.Randomized · Single-masked · TreatmentPhase 1RecruitingDrug: AZD1613, PlaceboHealthy1362026-09-23in 34 d2026-05-15
A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234NCT07220954Maximum observed plasma concentration (Cmax)Randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2 (high concentration), AZD6234 Formulation 3Healthy Participants192026-09-17in 28 d2026-08-13
A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy AdultsNCT07622433Area under concentration-time curve from time 0 to infinity (AUCinf)Randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP, Laroprovstat/ezetimibe FCDP-slow variantHealthy Participants182026-09-07in 18 d2026-07-28
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain CancerNCT03423628Incidence of dose-limiting toxicities (DLTs)Open-label · TreatmentPhase 1Active, not recruitingRadiation: Radiation Therapy, Radiation Therapy, Radiation Therapy · Drug: AZD1390, AZD1390, AZD1390Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)1592026-09-03in 14 d2026-07-17
A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in BrazilNCT06008353observationalDemographic Characteristics of the Cohort—Active, not recruitingOther: Observational studyExtensive-stage Small-cell Lung Cancer602026-08-31in 11 d2024-12-19
Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition BundleNCT06646419observationalTime to CID.—Active, not recruiting—COPD1,3682026-08-31in 11 d2026-08-13
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCNCT04995523Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parametersNon-randomized · Open-label · TreatmentPhase 1/2Active, not recruitingDrug: AZD2936Non-Small-Cell Lung Carcinoma2122026-08-28in 8 d2026-07-14
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsNCT07534592Area under concentration-time curve from time 0 to infinity (AUCinf) of atorvastatinNon-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Elecoglipron, Atorvastatin, RosuvastatinHealthy Participants482026-08-28in 8 d2026-06-24
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseNCT04711252Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1Randomized · Triple-masked · TreatmentPhase 3Active, not recruitingDrug: AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonistER-Positive HER2-Negative Breast Cancer1,3702026-08-24in 4 d2025-10-14
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyNCT06681324Number of participants with adverse eventsRandomized · Triple-masked · OtherPhase 2Active, not recruitingDrug: AZD7798 · Other: PlaceboCrohn's Disease242026-08-20today2026-06-01
Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)NCT06744335observationalThe proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).—Active, not recruiting—Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients, Routine Therapy Before and After the Diagnosis of CKD1,2832026-08-20today2026-07-08
Barriers and Facilitators of Persistence With Adjuvant OsimertinibNCT07542210observationalBarriers to persistence—Not yet recruiting—Non-small Cell Lung Cancer1002026-08-15—2026-05-14
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.NCT05267613Presence / absence of Erosive EsophagitisRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Nexium 20mg, Nexium 10mgErosive Esophagitis532026-08-14—2026-07-27
Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST CancerNCT07070128observationalAgreement between AI tool results and genetic test results—Recruiting—Breast Neoplasms8002026-08-11—2026-07-29
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightNCT07017179Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1).Randomized · Triple-masked · TreatmentPhase 2Active, not recruitingDrug: AZD6234, Placebo, AZD9550, Plocebo, AZD6234 in combination with AZD9550, PlaceboObesity/Overweight142026-08-06—2026-07-02
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaNCT06942910Change in log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baselineRandomized · Triple-masked · TreatmentPhase 2RecruitingDrug: Zibotentan/Dapagliflozin, DapagliflozinChronic Kidney Disease With High Proteinuria2242026-07-31—2026-04-17
Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemNCT07361276observationalUncontrolled blood pressure—Recruiting—Hypertension15,0002026-07-31—2026-07-24
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLCNCT07413757observationalPreferences weights for each attribute level evaluated in the DCE—Recruiting—Non-Small Cell Lung Cancer5902026-07-31—2026-07-13
D9319C00001- 1L OC Mono Global RCTNCT04884360Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard 1st line platinum based chemotherapy treatment.Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Olaparib · Other: Matching placeboOvarian Cancer3662026-07-27—2026-03-02
Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLCNCT07500987Safety and tolerability of [111In]-FPI 2107 following the administration of FPI 2053Open-label · DiagnosticPhase 1RecruitingDrug: [111In]-FPI-2107, FPI-2053EGFR Mutation-positive NSCLC122026-07-21—2026-06-17
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese ParticipantsNCT07222254Number of participants with adverse events (AEs), serious adverse events (SAEs) and adverse event of special interest (AESI)Randomized · Quadruple-masked · TreatmentPhase 1Active, not recruitingDrug: AZD0292, PlaceboHealthy Participants182026-07-20—2026-06-23
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisNCT05583227Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levelsRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingBiological: Tezepelumab, Tezepelumab · Other: PlaceboEosinophilic Esophagitis3682026-07-14actual—2026-07-30
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCCNCT07024680observationalThe primary objective is to characterize the real-world PFS (rwPFS) with either sunitinib or sorafenib.—RecruitingOther: Observational, None interventionPapillary Renal Cell Carcinoma1502026-07-14—2025-11-18
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsNCT06194448PFS (Progression-Free Survival)Open-label · TreatmentPhase 2Active, not recruitingDrug: Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel, RadiationLung Cancer762026-07-07actual—2026-08-19
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentNCT05261399Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Savolitinib, Osimertinib, Pemetrexed, Cisplatin, CarboplatinCarcinoma, Non-Small-Cell Lung3412026-07-06actual—2026-08-06
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARENCT06040099Progression Free Survival (PFS)Open-label · TreatmentPhase 2Active, not recruitingDrug: Durvalumab, Bevacizumab · Procedure: Transarterial Radioembolization (TARE)Hepatocellular Carcinoma (HCC)582026-07-01—2026-06-30
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in RussiaNCT05887011observationalDemographic and clinical characteristics of the population. NSCLC stage by TNM classification (% of patients). Patient status - locoregional recurrence and inoperable. Histology type. % of patients with known PD-L1 status and EGFR mutation status.—Active, not recruiting—Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)2,0002026-06-30—2026-05-27
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic AlterationsNCT06245837observationalTo assess treatment patterns in advanced/metastatic NSCLC in Russia and its change over time.—Active, not recruiting—Non-small-cell Lung Cancer1,5002026-06-30—2026-06-15
Study of Patient With Frequent COPD ExacerbationsNCT07221981observationalTo describe the baseline Demographic data characterisics of outpatients with moderate and severe COPD.—Active, not recruiting—Chronic Obstructive Pulmonary Disease (COPD)2,0382026-06-30—2026-07-09
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsNCT05048797Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, PemetrexedLocally Advanced or Metastatic Non-Small Cell Lung Cancer4542026-06-09actual—2026-07-10
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerNCT03682068Overall Survival (OS)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + GemcitabineUnresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer1,2462026-06-01—2026-05-28
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2NCT06346392Progression Free Survival (PFS) in all randomized participantsRandomized · Single-masked · TreatmentPhase 3Active, not recruitingDrug: AZD0901, AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, ApatinibGastric Cancer, Gastroesophageal Junction Cancer5942026-05-31actual—2026-07-09
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AgonistNCT06851858Percent change in body weight from baseline at Study Week 26Randomized · Triple-masked · TreatmentPhase 2Active, not recruitingDrug: AZD6234, Placebo to matchEndocrinology, Diabetes, Type II, Obesity692026-05-27—2026-03-03
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentNCT03847428Recurrence-free survival (RFS) for Arm A vs Arm CRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, Bevacizumab · Other: PlaceboHepatocellular Carcinoma9082026-05-15actual—2026-08-14
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid CardiomyopathyNCT06194825Percent change of serum TTR concentration from baselineRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Eplontersen, PlaceboTransthyretin Amyloid Cardiomyopathy642026-05-13actual—2026-06-09
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerNCT04612751Number of participants with DLTs; TEAEs and other safety parameters during the study.Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Datopotamab deruxtecan, Durvalumab, Carboplatin, AZD2936, MEDI5752, AZD7789Advanced or Metastatic NSCLC1552026-05-04actual—2026-07-27
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)NCT06606847Progression free survival (PFS) at 12 monthsOpen-label · TreatmentPhase 2Active, not recruitingDrug: Oleclumab, DurvalumabNon-Small Cell Lung Cancer302026-05-04actual—2026-05-15
Phase IIa Study Evaluating AZD7798 in Crohn's DiseaseNCT06450197CDAI remissionRandomized · Quadruple-masked · TreatmentPhase 2Active, not recruitingDrug: AZD7798 · Other: PlaceboModerate to Severe Crohn's Disease1202026-04-30actual—2026-08-04
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)NCT05883644Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs)Open-label · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, TremelimumabAdvanced Hepatocellular Carcinoma1112026-03-30actual—2026-04-30
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCNCT03997123Overall Survival (OS)Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Capivasertib, Paclitaxel, PlaceboTriple Negative Breast Neoplasms9232026-03-16—2025-12-22
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT05348577Overall Survival (OS) in the overall populationRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: capivasertib, docetaxel · Other: placeboProstate Cancer1,0352026-03-04—2025-01-27
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaNCT06502366Change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFAAsthma4222026-03-03—2026-02-13
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinNCT04960709To assess the safety and tolerability as evaluated by adverse events occurring throughout the study (Safety Run-In part)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, Tremelimumab, Enfortumab Vedotin · Procedure: Radical CystectomyMuscle Invasive Bladder Cancer7122026-03-02actual—2026-06-04
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCNCT05301842Progression Free Survival (PFS) for Arm A vs Arm CRandomized · Single-masked · TreatmentPhase 3Active, not recruitingDrug: Tremelimumab, Durvalumab, Lenvatinib · Procedure: Transarterial Chemoembolization (TACE)Hepatocellular Carcinoma7602026-02-23actual—2026-07-13
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of SaruparibNCT06899061Module 1: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf) of digoxin, furosemide, metformin and rosuvastatin when dosed alone and in combination with saruparibRandomized · Open-label · OtherPhase 1Active, not recruitingDrug: Saruparib, Digoxin, Furosemide, Metformin Hydrochloride, Rosuvastatin, RabeprazoleAdvanced Solid Malignancies412026-02-03actual—2026-07-30
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)NCT07128615Percentage of participants with immediate unsolicited adverse events (AE)Randomized · Quadruple-masked · PreventionPhase 1/2Active, not recruitingBiological: AZD4117, AZD5315 · Other: PlaceboInfluenza A4052026-01-28actual—2026-07-20
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR MutationsNCT05103605observationalOverall survival—Active, not recruitingDrug: OsimertinibNon Small Cell Lung Cancer2742026-01-15—2025-12-01
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)NCT05925530Resection rateOpen-label · TreatmentPhase 2Active, not recruitingDrug: DurvalumabNon-small Cell Lung Cancer1422026-01-12actual—2026-06-30
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCNCT05043090Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinibRandomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: savolitinib, durvalumab, sunitinibPapillary Renal Cell Carcinoma1482025-12-31actual—2026-05-22
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in EgyptNCT07144514observationalDescription of the lupus-affected population—Not yet recruiting—Systemic Lupus Erythematosus2762025-12-31—2025-08-27
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With DyslipidemiaNCT06238466Number of participants with adverse events (AEs) and serious adverse events (SAEs)Randomized · Double-masked · TreatmentPhase 1Active, not recruitingDrug: AZD1705 · Other: PlaceboCardiovascular982025-12-01actual—2026-08-05
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsNCT06271837Confirmed Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentPhase 2Active, not recruitingDrug: Trastuzumab deruxtecan, BevacizumabAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)1272025-11-28actual—2026-05-11
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyNCT05450692Overall Survival (OS)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Ceralasertib, Durvalumab, DocetaxelAdvanced or Metastatic Non-Small Cell Lung Cancer5942025-10-06actual—2026-07-13
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)NCT05771480Number of participants with Grade 3 or 4 possibly related adverse event (PRAE)Open-label · TreatmentPhase 3Active, not recruitingBiological: Durvalumab · Drug: Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxelBiliary Tract Cancer1422025-10-02actual—2026-07-29
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)NCT05374512Progression Free Survival (PFS)Randomized · Open-label · TreatmentPhase 3Active, not recruitingDrug: Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylateBreast Cancer6442025-08-25actual—2026-05-15
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusNCT04877691British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responseRandomized · Single-masked · TreatmentPhase 3Active, not recruitingDrug: Medi-546, PlaceboSystemic Lupus Erythematosus3672025-08-22actual—2026-07-27
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of CeralasertibNCT06754761To evaluate absolute bioavailability Ceralasertib and PK of Ceralasertib and [14C]-Ceralasertib after administration of oral dose of Ceralasertib and IV [14C]-Ceralasertib (Part AOpen-label · Basic sciencePhase 1Not yet recruitingDrug: [14C] AZD6738, AZD6738 / ceralasertibNeoplasm82025-08-08—2025-01-01
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)Randomized · Triple-masked · TreatmentPhase 3Active, not recruitingDrug: AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, RibociclibER-Positive HER2-Negative Breast Cancer3152025-06-30actual—2026-07-14
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsNCT05943106Incidence of Grade 3 or 4 Possibly related adverse events (PRAEs)Open-label · TreatmentPhase 3Active, not recruitingBiological: Durvalumab, BCGNon-Muscle- Invasive Bladder Cancer1002025-06-16actual—2026-08-13
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)NCT04191304results2026-07-10Time to First HES Worsening/Flare During the DB Treatment PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingBiological: Benralizumab, PlaceboHypereosinophilic Syndrome1342025-05-07actual—2026-07-10
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)NCT03944772Objective response rate (ORR)Non-randomized · Open-label · TreatmentPhase 2Active, not recruitingDrug: Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecanNon-Small Cell Lung Cancer2472025-05-06—2025-01-30
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder CancerNCT03528694The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of Disease free survival (DFS) in patients with NMIBCRandomized · Open-label · TreatmentPhase 3Active, not recruitingBiological: Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG)Non-muscle-invasive Bladder Cancer1,0182025-04-03actual—2026-07-07
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsNCT03737643results2026-06-09Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis SetRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+PaclitaxelAdvanced Ovarian Cancer1,4072025-03-17actual—2026-07-07
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerNCT05113251results2026-06-09Rate of Pathologic Complete Response (pCR).Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamideBreast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer9272025-03-12actual—2026-08-11
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer AgentsNCT02264678The number of subjects with adverse events/serious adverse eventsNon-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatinAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer3582025-03-04actual—2026-07-24
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerNCT04538742Occurrence of adverse events (AEs)- Part 1Randomized · Open-label · TreatmentPhase 1/2Active, not recruitingDrug: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab, TucatinibMetastatic Breast Cancer2452025-01-31actual—2025-12-08
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction CancerNCT04592913Event-free survival (EFS)Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, FLOT chemotherapyGastrointestinal Neoplasms, Esophagogastric Junction9572024-12-20actual—2025-12-24
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid CancerNCT04931654Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE)Randomized · Open-label · TreatmentPhase 1/2Active, not recruitingDrug: AZD7789Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer1362024-12-04actual—2025-10-09
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerNCT03742102results2026-02-02Dose Limiting Toxicity (DLT) EventsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2Active, not recruitingDrug: Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecanTriple Negative Breast Neoplasms2432024-11-29actual—2026-08-04
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast CancerNCT05498155To evaluate the efficacy, measured by pCR (pathological complete response) rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy, as assessed by central pathology review.Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Neoadjuvant Olaparib monotherapy group · Combination product: Neoadjuvant combination therapy with olaparib plus durvalumabBreast Cancer502024-11-20actual—2026-07-07
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCNCT05246514results2024-12-04ICR-assessed ORR (Objective Response Rate)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Trastuzumab deruxtecanHER2-mutant Non-Small Cell Lung Cancer722024-11-04actual—2026-08-18
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)NCT04765059results2026-01-13Progression Free Survival (PFS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatinNon-small Cell Lung Cancer982024-10-28actual—2026-07-07
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsNCT05457257results2025-12-19Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 4Active, not recruitingDrug: olaparib, enzalutamide, abiraterone acetate, PrednisoneMetastatic Castration-resistant Prostate Cancer432024-10-22actual—2026-04-21
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerNCT04351555results2026-06-05Major Pathological Response (MPR) - IASLC MethodRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Osimertinib, Cisplatin, Carboplatin, Placebo, PemetrexedNon-Small Cell Lung Cancer3582024-10-15actual—2026-06-05
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyNCT04493853Radiographic Progression-free Survival (rPFS)Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Capivasertib, Abiraterone Acetate · Other: PlaceboHormone-Sensitive Prostate Cancer1,0122024-10-07actual—2026-05-05
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid TumoursNCT04999969results2025-11-26Number of Participants With Adverse Events (AEs), Immune Mediated AEs (imAEs) and Serious AEs (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: AZD0171, Durvalumab, Gemcitabine, Nab-paclitaxelLocally Advanced or Metastatic Solid Tumours1262024-10-07actual—2026-08-19
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.NCT03616587The number of subjects with dose-limiting toxicity, as defined in the protocol.Randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: AZD9833, AZD9833, AZD9833 with palbociclib, AZD9833 with palbociclib, AZD9833 with everolimus, AZD9833 with everolimus, AZD9833 with abemaciclib, AZD9833 with abemaciclib, AZD9833 with capivasertib, AZD9833 with capivasertib, AZD9833 with ribociclib, AZD9833 with ribociclib, AZD9833 with anastrozole, AZD9833 with anastrozoleER+ HER2- Advanced Breast Cancer3962024-09-16actual—2026-08-18
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyNCT03334617results2025-10-27Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, CediranibNon-Small Cell Lung Cancer5282024-09-13actual—2025-10-27
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibNCT03778229results2026-02-10Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis SetRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: osimertinib, savolitinib, placeboCarcinoma3672024-08-23actual—2026-04-23
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform NeurofibromasNCT04924608results2025-10-20Confirmed Partial and Complete Response Rate (ORR) by End of Cycle 16 Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) in Participants With NF1 Who Have Symptomatic, Inoperable PN.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Selumetinib · Other: PlaceboNeurofibromatosis 1, Plexiform Neurofibroma (PN)1452024-08-05actual—2026-03-23
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyNCT05941897Objective response rate (ORR)Open-label · TreatmentPhase 2Active, not recruitingDrug: Ceralasertib, DurvalumabAdvanced or Metastatic NSCLC392024-07-29actual—2026-06-17
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)NCT05104866results2026-02-04Progression-Free SurvivalRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Dato-DXd, Capecitabine, Gemcitabine, Eribulin, VinorelbineBreast Cancer7322024-07-24actual—2026-05-05
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerNCT04269200results2025-12-23Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator AssessmentsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: olaparib, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel · Biological: durvalumabEndometrial Neoplasms8052024-07-08actual—2026-08-07
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsNCT03706690results2025-02-12Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Durvalumab · Other: PlaceboCarcinoma, Non-Small-Cell Lung4072024-06-23actual—2026-08-06
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCNCT03732677results2025-07-03Pathologic Complete Response (pCR) Rates at Time of CystectomyRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Durvalumab, Cisplatin, GemcitabineMuscle Invasive Bladder Cancer1,0632024-04-29actual—2026-07-17
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionNCT05061134results2025-05-21Main Study: Objective Response Rate (ORR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Ceralasertib · Biological: DurvalumabMelanoma1942024-04-12actual—2025-07-31
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerNCT04494425results2025-04-02Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low PopulationRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-PaclitaxelAdvanced or Metastatic Breast Cancer8662024-03-18actual—2026-03-04
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerNCT04739761results2025-05-16Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Trastuzumab DeruxtecanBreast Cancer5062024-02-08actual—2026-08-11
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)NCT05171816results2025-06-29Radiological Progression Free Survival (rPFS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: olaparib, abiraterone acetateMetastatic Castration-resistant Prostate Cancer1102024-01-22actual—2026-06-18
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT03703297results2025-08-01Durvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Durvalumab, Tremelimumab · Other: PlaceboSmall Cell Lung Cancer7302024-01-15actual—2025-11-21
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)NCT03521154results2025-04-03Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mgNon Small Cell Lung Cancer (Stage III)2162024-01-05actual—2026-08-04
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaNCT04075292results2025-01-30Progression Free Survival (PFS) Assessed by BICRRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Acalabrutinib, Rituximab, ChlorambucilUntreated Chronic Lymphocytic Leukemia1552024-01-03actual—2026-06-16
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)NCT05460273results2025-06-13Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2Active, not recruitingDrug: Datopotamab Deruxtecan (Dato-DXd)Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer1192023-11-07actual—2026-07-02
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursNCT05514132The number of subjects with dose-limiting toxicity, as defined in the protocol.Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Ceralasertib, DurvalumabAdvanced Solid Tumours142023-10-20actual—2026-08-11
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaNCT03778957Progression Free Survival (PFS) for Arm B vs Arm CRandomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, Bevacizumab · Other: Placebo · Procedure: Transarterial Chemoembolization (TACE)Hepatocellular Carcinoma7242023-09-11actual—2026-07-15
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerNCT04556773Occurrence of adverse events (AEs)- Part 1Non-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, CapecitabineMetastatic Breast Cancer1382023-08-16actual—2026-08-03
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.NCT04157348results2025-01-14Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingBiological: Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to BenralizumabEosinophilic Granulomatous Vasculitis1402023-08-10actual—2026-08-12
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCNCT03819465Assessment of AEs by CTCAE v5.0Randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936Metastatic Non-Small Cell Lung Cancer (NSCLC)1752023-05-23actual—2026-05-12
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerNCT04305496results2025-10-27Progression Free Survival: Overall Population (Months) in the Global CohortRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Fulvestrant, Capivasertib, PlaceboLocally Advanced (Inoperable) or Metastatic Breast Cancer8182023-05-09actual—2026-04-30
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)NCT04035486results2024-08-06Adverse Events Graded by Common Terminology Criteria for Adverse Event v5 (Safety Run-In Treatment Arms Only)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/CisplatinNon-Small Cell Lung Cancer5872023-04-03actual—2025-10-10
Durvalumab and Tremelimumab for Pediatric MalignanciesNCT03837899results2024-03-19Dose-Finding Phase: Maximum Serum Concentration (Cmax) of DurvalumabNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2Active, not recruitingDrug: Durvalumab / Tremelimumab Combination TherapyPediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies502023-02-28actual—2026-07-07
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating MutationsNCT04639219results2024-02-15Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Trastuzumab deruxtecanAdvanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast1022023-01-25actual—2026-03-23
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell MalignanciesNCT03932331results2025-03-20Phase I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2Active, not recruitingDrug: AcalabrutinibPhase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia1052022-12-22actual—2026-04-20
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCNCT04606771results2024-09-24Objective Response Rate (ORR)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Osimertinib + Savolitinib, Savolitinib + PlaceboNon-Small Cell Lung Cancer302022-12-21actual—2026-07-30
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerNCT03800134Pathological Complete Response (pCR) in modified intent-to-treat (mITT) populationRandomized · Double-masked · TreatmentPhase 3Active, not recruitingDrug: Durvalumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine · Other: Placebo · Procedure: SurgeryNon-Small Cell Lung Cancer8252022-11-10actual—2025-06-11
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)NCT03003962results2023-12-26Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatinNon Small Cell Lung Carcinoma NSCLC6692022-10-27actual—2026-06-11
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerNCT04214288results2023-12-12Progression-free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: AZD9833, FulvestrantAdvanced ER-Positive HER2-Negative Breast Cancer2402022-08-30actual—2026-06-15
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)NCT04590235Adverse eventsNon-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: SelumetinibNeurofibromatosis 1, Neurofibroma Plexiform322022-08-16actual—2026-08-18
Study of AZD2811 + Durvalumab in ES-SCLCNCT04745689results2025-03-27Maintenance Participants Alive and Progression Free (APF12) Per RECIST 1.1 [Efficacy]Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Durvalumab, AZD2811, Carboplatin, Cisplatin, EtoposideSmall-Cell Lung Cancer312022-06-18actual—2026-07-06
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerNCT04590963results2023-11-18Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis SetRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Monalizumab, Cetuximab · Other: PlaceboSquamous Cell Carcinoma of the Head and Neck3702022-05-11actual—2026-06-01
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.NCT02511106results2021-07-27Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mgStage IB-IIIA Non-small Cell Lung Carcinoma6822022-04-11actual—2026-03-30
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform NeurofibromasNCT05101148Selumetinib area under the plasma concentration-time curve from zero to 12 hours post-dose (AUC0-12)Open-label · TreatmentPhase 1Active, not recruitingDrug: SelumetinibNeurofibromatosis Type 1242022-04-06actual—2026-05-20
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.NCT02734004results2023-10-13Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 1/2Active, not recruitingDrug: Olaparib, MEDI4736, BevacizumabOvarian, Breast, SCLC, Gastric Cancers2642021-09-17actual—2026-07-14
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaNCT03298451results2023-06-18Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mgRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)Hepatocellular Carcinoma1,3242021-08-27actual—2026-07-27
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)NCT03875235results2023-04-13Overall Survival (OS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Durvalumab, PlaceboBiliary Tract Neoplasms8102021-08-11actual—2026-05-26
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerNCT03732820results2023-06-15Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator AssessmentRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: olaparib, abiraterone acetateMetastatic Castration-resistant Prostate Cancer8952021-07-30actual—2026-08-18
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).NCT03164616results2022-04-07Progression-Free Survival (PFS); D + SoC Compared With SoC AloneRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatinNon Small Cell Lung Cancer NSCLC1,1862021-03-12actual—2026-03-13
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)NCT03775486results2022-12-12Progression-free SurvivalRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatinNon-small Cell Lung Cancer NSCLC4012021-01-11actual—2026-05-01
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.NCT03330847results2022-03-22Progression-free Survival Per Stratum (BICR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).Metastatic Triple Negative Breast Cancer2732020-11-13actual—2026-07-02
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)NCT03459846results2022-10-26Progression-free Survival (PFS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 2Active, not recruitingDrug: Durvalumab, Olaparib, PlaceboUrinary Bladder Neoplasms1542020-10-15actual—2026-08-05
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)NCT02542293results2022-05-24Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis SetRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingBiological: Durvalumab +Tremelimumab · Drug: Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatinNon Small Cell Lung Carcinoma NSCLC9532020-09-21actual—2026-08-06
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerNCT02032823results2021-12-08Invasive Disease Free Survival (IDFS)Randomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Olaparib, PlaceboBreast Cancer1,8372020-03-27actual—2026-07-14
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerNCT02546661Module A: The frequency and nature of adverse events related to AZD4547 monotherapy.Randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, SelumetinibMuscle Invasive Bladder Cancer1172020-03-18actual—2025-12-29
AZD9291 in Combination With Ascending Doses of Novel TherapeuticsNCT02143466Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and Tolerability of AZD9291 when given in combination with AZD6094 or selumetinibNon-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094Advanced Non Small Cell Lung Cancer3442020-03-04actual—2026-07-20
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerNCT02516241results2021-05-13To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis SetRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, GemcitabineUrothelial Cancer1,1262020-01-27actual—2026-07-14
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)NCT03043872results2021-03-04Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EPRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Durvalumab, Tremelimumab, Carboplatin, Cisplatin, EtoposideSmall Cell Lung Carcinoma Extensive Disease9872020-01-27actual—2026-07-16
Savolitinib vs. Sunitinib in MET-driven PRCC.NCT03091192results2020-07-10Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Savolitinib, SunitinibCarcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors602019-08-18actual—2026-07-14
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)NCT02453282results2019-11-29Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC ChemotherapyRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingBiological: MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Tremelimumab · Drug: Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + CarboplatinNon-Small-Cell Lung Carcinoma NSCLC1,1182018-10-04actual—2026-08-06
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.NCT01844986results2019-07-09Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗Phase 3Active, not recruitingDrug: Olaparib 300mg tabletsNewly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy4502018-05-17actual—2025-12-10
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyNCT01874353results2018-02-07Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Olaparib 300mg tablets, Placebo to match olaparib 300mgPlatinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy3272016-09-19actual—2026-07-29
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCNCT01933932results2017-08-29Progression-Free Survival (PFS)Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: Selumetinib, Docetaxel, Placebo, Pegylated G-CSFLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV5102016-06-07actual—2026-07-21
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian CancerNCT01081951results2012-12-10Progression Free Survival (PFS)Randomized · Open-label · TreatmentPhase 2Active, not recruitingDrug: olaparib, paclitaxel, carboplatin, paclitaxel, Drug: carboplatinOvarian Cancer1622011-10-10actual—2026-08-05
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursNCT00750841To assess the steady-state PK parameters of cediranib in the presence and absence of rifampicinNon-randomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: cediranibSolid Tumors642009-07-30actual—2026-08-17
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.NCT00099437results2010-06-15Time to Progression (TTP)Randomized · Quadruple-masked · TreatmentPhase 3Active, not recruitingDrug: FulvestrantBreast Cancer7362009-02-27actual—2026-06-11
Phase I Comparative Bioavailability StudyNCT00777582PK Phase Primary Outcome: To determine the comparative bioavailability of a new tablet formulation of AZD2281 compared to the existing capsule formulationRandomized · Open-label · Basic sciencePhase 1Active, not recruitingDrug: AZD2281Solid Tumors1972009-02-06actual—2026-08-06
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid MalignanciesNCT00463814Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Part A and Part BRandomized · Open-label · TreatmentPhase 1Active, not recruitingDrug: AZD6244Tumor, Cancer582008-06-17actual—2026-05-29
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT06839872Objective Response Rate (ORR) in participants with CLL/SLL.Open-label · TreatmentPhase 2Withdrawnsponsor's stated reason: AstraZeneca has made the decision to cancel the trial.Drug: Pirtobrutinib, AcalabrutinibChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma02028-07-28in 708 d2025-06-05

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19

Related →Filings market-wide (EVX)Red flags (FLAG)Documents (DOC)Legal & controls (LGCT)